

(19)



Europäisch s Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 074 564 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

07.02.2001 Bulletin 2001/06

(51) Int. Cl.⁷: C07K 19/00, C07K 14/47,
C07K 16/00, G01N 33/566,
G01N 33/53

(21) Application number: 99900301.5

(22) Date of filing: 13.01.1999

(86) International application number:
PCT/JP99/00089(87) International publication number:
WO 99/54360 (28.10.1999 Gazette 1999/43)

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

- ONO, Yukitsugu,
Ajinomoto Co., Inc.
Kawasaki-shi, Kanagawa 210-0801 (JP)

(30) Priority: 23.04.1998 JP 11396298

- ISHII, Koichi,
Ajinomoto Co., Inc.
Kawasaki-shi, Kanagawa 210-0801 (JP)

(71) Applicant: Ajinomoto Co., Inc.

Tokyo 104-0031 (JP)

- TANAKA, Akiko,
Ajinomoto Co., Inc.
Kawasaki-shi, Kanagawa 210-0801 (JP)

(72) Inventors:

- FUKUCHI, Naoyuki,
Ajinomoto Co., Inc.
Kawasaki-shi, Kanagawa 210-0801 (JP)
- FUTAKI, Fumie,
Ajinomoto Co., Inc.
Kawasaki-shi, Kanagawa 210-0801 (JP)
- KITO, Morikazu,
Ajinomoto Co., Inc.
Kawasaki-shi, Kanagawa 210-0801 (JP)
- SATO, Seiichi,
Ajinomoto Co., Inc.
Kawasaki-shi, Kanagawa 210-0801 (JP)
- KAJIURA, Takayuki,
Ajinomoto Co., Inc.
Kawasaki-shi, Kanagawa 210-0801 (JP)

- SHINOZAKI, Junko,
Ajinomoto Co., Inc.
Kawasaki-shi, Kanagawa 210-0801 (JP)
- JOJIMA, Yasuko,
Ajinomoto Co., Inc.
Kawasaki-shi, Kanagawa 210-0801 (JP)

(74) Representative:

Nicholls, Kathryn Margaret et al
MEWBURN ELLIS
York House
23 Kingsway
London WC2B 6HP (GB)

(54) **SUBSTANCE WITH ANTITHROMBOTIC ACTIVITY AND METHOD FOR DETECTING GLYCOKALLIDIN**

(57) A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a reaction vessel in the presence of botrocetin is bound to a chimeric protein constructed by fusing the carboxyl terminal of a partial protein containing the von Willebrand factor-binding site of glycoprotein Ib with the amino terminal of the Fc region of an immunoglobulin molecule. Then the Fc region of the above immunoglobulin molecule is detected to thereby detect the binding between the von Willebrand factor and the glycoprotein Ib or inhibition of this binding.

Description**Technical Field**

5 [0001] The present invention relates to substance with antithrombotic activity and method for detecting glycocalicin. More precisely, it relates to a method for detecting or measuring a substance that inhibits binding of von Willebrand factor and glycoprotein Ib, and means directly used for carrying out the method.

Background Art

10 [0002] The global number of patients with thromboses such as myocardial infarction, cerebral infarction and peripheral artery occlusive disease is very large, and these diseases are very significant diseases to be diagnosed and treated. Platelets play a fundamental role for the onset of these thromboses. In general, if vascular endothelial cells in blood vessel cavities are impaired by arteriosclerotic lesion or the like, platelets will adhere to the impaired region to cause activation, and thus there are formed thrombocytic thrombi, which eventually develop into occlusive lesions.

15 [0003] As one of the methods for detecting activation of platelets, there is a method of measuring glycocalicin concentration in plasma. Glycocalicin is a protein consisting of an enzymatically cleaved extracellular portion of a membrane glycoprotein present on surfaces of platelets, glycoprotein Ib α chain, and has a molecular weight of about 135 kDa. It is known that glycocalicin concentration in plasma is increased by impairment or activation of platelets, and it is currently used as a marker for detecting presence or absence of thrombotic diseases in clinical diagnosis. (J.H. Beer *et al.*, *Blood*, 83, 691-702, 1994; S. Kunishima *et al.*, *Clin. Chem.*, 37, 169-172, 1991).

20 [0004] Many measurement methods of glycocalicin concentration have been reported, and any of these are based on ELISA (enzyme-linked immunosorbent assay) technique, wherein glycocalicin is detected by the sandwiching method utilizing two kinds of monoclonal antibodies directed to glycocalicin (J.H. Beer *et al.*, *supra*; S. Kunishima *et al.*, *supra*). Briefly, first monoclonal antibodies are immobilized on a 96-well plate or the like as a solid phase, blocked with a protein such as bovine serum albumin (BSA), and then added with patient's plasma (or serum) to be measured. Glycocalicin specifically binds to the monoclonal antibodies immobilized on the solid phase. The plate is washed, and added with second monoclonal antibodies labeled with an enzyme such as alkaline phosphatase and peroxidase or biotin so that the second antibodies should specifically bind to the glycocalicin bound to the first monoclonal antibodies.

25 [0005] After washing, the plate is added with a substrate that can be converted into a substance exhibiting specific absorbance in a UV or visible region, fluorescence or luminescence with the enzyme used as the label of the second antibodies to perform an enzymatic reaction. Since the amount of glycocalicin in the patient's plasma and the binding amount of the second antibodies show positive correlation, the concentration of glycocalicin in the patient's plasma can be measured by quantifying the reaction product produced by the enzymatic reaction. A measurement method for glycocalicin by competitive ELISA utilizing one kind of anti-glycocalicin antibodies has also been reported (H. Bessos *et al.*, *Thromb. Res.*, 59, 497-507, 1990). However, the IC₅₀ value of the glycocalicin concentration showing competitive inhibition is about 4 μ g/ml, and this makes the above measurement unusable for the measurement of the glycocalicin concentration in plasma (it is about 2 μ g/ml in a healthy subject, J.H. Beer *et al.*, *supra*).

30 [0006] The aforementioned glycocalicin quantification methods based on the sandwich technique are widely used at present. However, when a similar measurement system is desired to be newly prepared, it is necessary to obtain two kinds of anti-glycocalicin monoclonal antibodies having different recognition sites. Commercially available monoclonal antibodies are generally very expensive, and the preparation of monoclonal antibodies requires much labor such as acquisition of glycocalicin for immunization, acquisition of hybridoma from a spleen of immunized mouse and screening of a monoclonal antibody-producing cell. Further, it is impossible to measure an absolute value of glycocalicin concentration from the amount of the enzymatic reaction in the aforementioned sandwich ELISA method, and in many cases, it is necessary to measure glycocalicin of several kinds of known concentrations to obtain a calibration curve, and then it is necessary to calculate a concentration in a test sample to be measured based on comparison with the calibration curve. Therefore, it is important to establish a method capable of measuring an absolute concentration of glycocalicin in a simple manner without the complicated preparation of monoclonal antibodies, from a viewpoint of wide use in clinical diagnosis.

35 [0007] Further, in an early stage of onset of thrombosis, von Willebrand factor in blood binds to subendothelial tissues (collagen etc.) exposed due to impairment of vascular endothelial cells, and the membrane glycoprotein, glycoprotein Ib, on platelets binds to the von Willebrand factor. Thus, the platelets adhere to blood vessel walls, and they are activated (J.P. Cean *et al.*, *J. Lab. Clin. Med.*, 87, 586-596, 1976; K.J. Clemetson *et al.*, *Thromb. Haerhost.*, 78, 266-270, 1997). Therefore, it is an important target of antithrombotic drugs for treating or preventing thromboses to inhibit the binding of von Willebrand factor and glycoprotein Ib. However, there are few substances that have been proven to exhibit antithrombotic property by inhibiting the binding of the both proteins.

40 [0008] It has been reported that a recombinant protein VCL that has a sequence of from the 504th to 728th amino

acid residues of von Willebrand factor shows an antithrombotic action by inhibiting the binding of von Willebrand factor and glycoprotein Ib (K. Azzam *et al.*, *Thromb. Haemost.*, 73, 318-323, 1995). Further, it has also been reported that a monoclonal antibody AJvW-2 directed to human von Willebrand factor exhibits an antithrombotic activity by specifically binding to von Willebrand factor without showing hemorrhagic tendency (S. Kageyama *et al.*, *Br. J. Pharmacol.*, 122, 165-171, 1997; WO 96/17078). Furthermore, the protein AS1051 derived from snake venom specifically binds to the platelet glycoprotein Ib to similarly exhibit an antithrombotic property without showing hemorrhagic tendency (N. Fukuchi *et al.*, WO 95/08573).

[0008] Further, aurintricarboxylic acid (ATA), which is a pigmental compound, has been reported to show an activity for inhibiting the binding of von Willebrand factor and glycoprotein Ib (M.D. Phillips *et al.*, *Blood*, 72, 1989-1903, 1988).

10 However, it is known that its binding specificity is not high (K. Azzam *et al.*, *Thromb. Haemost.*, 75, 203-210, 1996; D. Mitra *et al.*, *Immunology*, 87, 581-585, 1996; R.M. Lozano *et al.*, *Eur. J. Biochem.*, 248, 30-36, 1997), and that the inhibition activity is exhibited by a polymerized macromolecule fraction (M. Weinstein *et al.*, *Blood*, 78, 2291-2298, 1991; Z. Gua *et al.*, *Thromb. Res.*, 71, 77-88, 1993; H. Matsuno *et al.*, *Circulation*, 96, 1299-1304, 1997) etc.

[0009] As described above, although it is an important target of antithrombotic drugs to inhibit the binding of von Willebrand factor and glycoprotein Ib, there is no low molecular weight compound that has reported to inhibit the binding of the both and have an antithrombotic activity, and therefore it is important to find out such a substance for attempting treatment and prevention of thromboses.

[0010] As a non-proteinaceous substance that inhibits the binding of von Willebrand factor and glycoprotein Ib, aurintricarboxylic acid (ATA) can be mentioned. However, it is known that it exhibits the inhibitory activity as a polymerized macromolecular substance as already described above. M. Weinstein *et al.* (*Blood*, 78, 2291-2298, 1991) investigated an activity of ATA fractionated by gel filtration for inhibiting the ristocetin-induced aggregation, which is von Willebrand factor and glycoprotein Ib dependent platelet aggregation, and concluded that a polymer having a molecular weight of 2500 had the strongest activity. They also showed that fractions eluted as low molecular weight fractions in the gel filtration scarcely have the activity (Figs. 1 and 3 in the aforementioned reference). Moreover, in this report, neither a specific structure nor molecular weight of the ATA polymer showing the activity was specified. It is considered that there are no ATA derivatives exhibiting the inhibitory activity for the binding of von Willebrand factor and glycoprotein Ib among those of which structure can be specified, in view of the facts that, although the synthesis of the ATA monomer has already been reported by R.D. Haugwitz (WO 91/06589), no data were reported so far for demonstrating the inhibition of the binding of von Willebrand factor and glycoprotein Ib as for the monomer or a polymer of which structure can be specified, and evaluation of the activity has been reported by using a gel filtration fraction of ATA polymer even in a recent study (T. Kawasaki *et al.*, *Amer. J. Hematol.*, 47, 6-15, 1994).

[0011] In the aforementioned report by M. Weinstein *et al.* (*Blood*, 78, 2291-2298, 1991), it is described that presence of many negative electric charges (polyanion) and presence of many aromatic rings (polyaromatic) are necessary for the inhibition of the binding of von Willebrand factor and glycoprotein Ib. The fact that the abundance of negative electric charges is likely to inhibit the binding of von Willebrand factor and glycoprotein Ib is also consistent with the fact that heparin, which is a polysaccharide having negative electric charges, inhibits the binding of von Willebrand factor and glycoprotein Ib (M. Sobel *et al.*, *J. Clin. Invest.*, 87, 1787-1793, 1991). In this report, it is also reported that the activity for inhibiting the binding of von Willebrand factor and glycoprotein Ib is reduced, as the molecular weight of heparin becomes smaller.

[0012] Heparin is originally a substance inhibiting thrombin, which is a blood aggregation factor, and the blood aggregation factor X (factor Xa). Although a heparin derivative that was imparted with higher selectivity for the binding of von Willebrand factor and glycoprotein Ib has also been reported (M. Sobel *et al.*, *Circulation*, 93, 992-999, 1996), the average molecular weight of that substance is 10,000 or more.

[0013] Among substances that are likely to bind to proteins, there is also reported a substance that shows the selective inhibitory activity to some extent for the binding of von Willebrand factor and glycoprotein Ib. It was demonstrated that Evans Blue, which is a pigmental compound, selectively inhibited the platelet aggregation in which von Willebrand factor (factor VIII in this reference) was involved (E.P. Kirby *et al.*, *Thrombos. Diathes. Haemorrh.*, 34, 770-779, 1975). However, the experimental results contained in this reference all concerned platelet aggregation under a condition not containing blood plasma, and no reference was made for the activity under a condition where plasma proteins are present. Evans Blue is originally a substance that very firmly binds to serum albumin, and such a property provides its use as means for measurement of blood volume, blood leak from blood vessels in living bodies and so forth (M. Gregersen & R.A. Rawson, *Physiol. Reviews*, 39, 307, 1959). That is, when treatment of living bodies, for example, humans, is intended, such substances that strongly bind to proteins in plasma as mentioned above would not show the effect at all. As such substances, there are sulfobacin (T. Kamiyama *et al.*, *J. Antibiot.*, 48, 924-928, 1995) and so forth. Although sulfobacin showed the specificity for the binding of von Willebrand factor and glycoprotein Ib to some extent according to the above reference, it must not show the activity due to the binding to plasma proteins in blood or blood plasma in view of its detergent-like structure. In fact, its inhibitory activity for the platelet aggregation in plasma was not shown in the aforementioned reference.

[0014] As described above, any low molecular compounds have not been known so far, which can inhibit the binding of von Willebrand factor and glycoprotein Ib in living bodies. Assuming drugs against thrombotic diseases for inhibiting the binding of von Willebrand factor and glycoprotein Ib, if they are used as an injection, they may be a macromolecular compound such as proteins or polymers. However, in order to create a drug of the same mechanism of action that can be orally administered, it is important to find a low molecular weight substance that is not a polymer and completely and selectively inhibits von Willebrand factor and glycoprotein Ib dependent platelet aggregation in blood (in plasma).

[0015] However, such compounds have not been found so far. As a reason for this, there can be mentioned the fact that any assay system enabling screening of such a substance in a simple manner has not existed.

[0016] As will be described later, in conventionally used assay methods for detecting the binding of von Willebrand factor and glycoprotein Ib, ^{125}I -labeled von Willebrand factor are bound to platelets or formalin-fixed platelets. However, such methods suffer from complexity of using the radioactive isotope, and difficulty of obtaining a large amount of sample, i.e., difficulty that blood must be collected from an animal, and platelets must be obtained from it. The methods generally used so far and means for solving the problems thereof will be specifically described below.

[0017] The binding of von Willebrand factor and glycoprotein Ib is not observed under a usual condition, and it is considered that it occurs only under a condition where shear stress is induced in a blood flow (T.T. Vincent *et al.*, *Blood*, 65, 823-831, 1985). However, as a method for artificially making it possible to observe the binding of the both proteins, there are known addition of an antibiotic, ristocetin (M.A. Howard and B.G. Firkin, *Thromb. Haemost.*, 26, 362-369, 1971), and addition of a protein derived from snake venom, botrocetin (M.S. Read *et al.*, *Proc. Natl. Acad. Sci. USA*, 75, 4514-4518, 1978). That is, the both substances are known as a substance that binds to a specific site of von Willebrand factor to cause a structural change of the von Willebrand factor, thereby causing the binding of the von Willebrand factor and glycoprotein Ib, which does not occur under a usual condition. As a method for observing the binding of the both proteins, there is the following method reported by Fujimura *et al.* (Y. Fujimura *et al.*, *Blood*, 77, 113-120, 1991).

[0018] That is, human von Willebrand factor is labeled with ^{125}I in a conventional manner, and allowed to bind to formalin-fixed platelets in the presence of a certain amount of ristocetin or botrocetin. This binding occurs due to the specific binding of the von Willebrand factor to glycoprotein Ib on the surfaces of the immobilized platelets, and after unbound von Willebrand factor are removed by washing, the amount of the both proteins bound to each other can be measured by measuring the amount of ^{125}I . Miura *et al.* detected the binding of the both proteins by a similar method,

wherein platelets were immobilized on a 96-well plate via immobilized anti-platelet membrane protein antibodies instead of the use of formalin-fixed platelets (S. Miura *et al.*, *Anal. Biochem.*, 236, 215-220, 1996). Further, Matsui *et al.* reported a method of binding glyocalicin, which is a partial protein of the extracellular portion of glycoprotein Ib α chain in the presence of botrocetin, to von Willebrand factor bound to collagen immobilized as a solid phase (T. Matsui *et al.*, *J. Biochem.*, 121, 376-381, 1997). Furthermore, Moriki *et al.* produced a recombinant protein expressing cell that expressed glycoprotein Ib on the membrane, and reported that ^{125}I -labeled von Willebrand factor bound to the glycoprotein Ib on the membrane in the presence of botrocetin. Moriki *et al.* further produced a cell expressing glycoprotein Ib having a mutation in the amino acid sequence, which bound to von Willebrand factor without any inducing agent, and performed a binding experiment. However, the binding amount was very small compared with the binding amount in the presence of botrocetin or ristocetin (T. Moriki *et al.*, *Blood*, 90, 698-705, 1997).

[0019] As described above, all of the methods reported so far for detecting the binding of von Willebrand factor and glycoprotein Ib with high sensitivity are methods by obtaining a large amount of platelets or glycoprotein Ib expressing cells and detecting the binding of von Willebrand factor to them. However, it is extremely laborious to routinely prepare a large amount of platelets or such cells, and therefore it is necessary to develop a method for detecting the binding of von Willebrand factor and glycoprotein Ib in a simpler manner.

[0020] Further, all of the conventionally used methods are exclusively methods utilizing addition of a binding inducing substance such as botrocetin or ristocetin to a liquid phase. However, the amount of botrocetin or ristocetin changes the amount of the binding of von Willebrand factor and glycoprotein Ib. Moreover, if a large number of binding experiments are performed by using a 96-well plate, for example, these methods utilizing addition of the inducing substance to the liquid phase are laborious. Furthermore, when the aforementioned low molecular weight substance inhibiting the binding of von Willebrand factor and glycoprotein Ib is searched, an extremely large number of binding experiments must be performed, and therefore it is also important from this viewpoint to solve the aforementioned problem.

[0021] As already stated, a true inhibition substance with low molecular weight for the binding of von Willebrand factor and glycoprotein Ib has not been discovered yet. The term "true inhibition substance" used herein means a substance specifically inhibiting the binding of von Willebrand factor and glycoprotein Ib, but does not mean a substance that inhibits the binding of von Willebrand factor and glycoprotein Ib in a non-specific manner, even though it may inhibit the binding of von Willebrand factor and glycoprotein Ib, like substances that generally change structures of proteins such as protein denaturing substances and detergents or substances that non-specifically bind to proteins.

[0022] As described above, such true inhibition substances for the binding of von Willebrand factor and glycoprotein

Ib have been found among antibodies, proteins derived from snake venom, pigmental substances such as aurintricarboxylic acid (ATA), of which active body is a substance having a high molecular weight. However, no such substance has been known among low molecular weight substances, for example, those having a molecular weight of 2000 or less, in particular, those having a molecular weight of 1000 or less, which are useful for oral administration. Therefore, it has been desired to develop an evaluation system capable of quickly screening such substances.

Disclosure of the Invention

[0023] The problems of the aforementioned technical background are summarized in the following three points.

- (1) Although methods for quantification of glycocalicin is important for diagnosis of thromboses, conventional highly sensitive methods are sandwich ELISA methods. Therefore, two kinds of monoclonal antibodies having different recognition sites are required, and a calibration curve prepared with a standard substance is required for the quantification.
- (2) It is important to discover a low molecular weight inhibition substance for the binding of von Willebrand factor and glycoprotein Ib, and use it as a drug, in view of the treatment and prevention of thromboses. However, no low molecular weight drug has been known so far, which targets the inhibition of the binding of von Willebrand factor and glycoprotein Ib and is reported to have antithrombotic activity.
- (3) In order to find out such a drug as mentioned in the above (2), large number of binding inhibition experiments must be performed for von Willebrand factor and glycoprotein Ib. However, the conventionally known methods are complicated, and may have problems concerning accuracy and sensitivity.

[0024] The present invention has been accomplished from the aforementioned viewpoints, and an object of the present invention is to provide a method for detecting the binding of von Willebrand factor and glycoprotein Ib in a simple manner, a simple method for measurement of glycocalicin, and a simple method for measurement of a substance that can be an antithrombotic drug of which working point is the inhibition of the binding of von Willebrand factor and glycoprotein Ib, as well as means for use in these measurement methods.

[0025] The inventors of the present invention assiduously studied in order to achieve the aforementioned object. That is, a protein expression system based on an animal cell was prepared first for obtaining a chimeric molecule consisting of a partial protein of glycoprotein Ib α chain bound to the Fc region of immunoglobulin molecule (hereinafter referred to as "chimeric protein"). Further, they found that, if von Willebrand factor was immobilized in the presence of botrocetin, the aforementioned chimeric protein, i.e., glycoprotein Ib molecule, specifically bound to the immobilized von Willebrand factor without a binding inducing substance in a liquid phase, and that a binding test can be performed in a simple manner to measure the binding amount by labeling commercially available inexpensive anti-immunoglobulin Fc antibodies or directly labeling the chimeric protein, and thus accomplished the present invention.

[0026] That is, the first method according to the present invention is a method for detecting binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding, comprising the steps of immobilizing von Willebrand factor in a reaction vessel in the presence of a substance inducing the binding of von Willebrand factor and glycoprotein Ib, and, reacting the immobilized von Willebrand factor with glycoprotein Ib.

[0027] The second method according to the present invention is a method for detecting binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding, comprising the steps of binding a chimeric protein that consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Ib α chain at its carboxyl terminus or the chimeric protein labeled with a labeling substance to von Willebrand factor immobilized in a reaction vessel, and detecting the Fc region of the immunoglobulin molecule or the labeling substance.

[0028] The third method according to the present invention is a method for detecting binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding, comprising the steps of immobilizing a chimeric protein that consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Ib α chain at its carboxyl terminus in a reaction vessel, binding von Willebrand factor or labeled von Willebrand factor to the chimeric protein, and detecting bound von Willebrand factor or the labeling substance.

[0029] In a preferred embodiment of the second method or the third method, when the chimeric protein is allowed to bind to von Willebrand factor, or prior to the binding, a substance that induces the binding of von Willebrand factor and glycoprotein Ib is added to the reaction vessel.

[0030] As the substance that induces the binding of von Willebrand factor and glycoprotein Ib, botrocetin, ristocetin or the both substances can be mentioned.

[0031] Further, in another embodiment of the second method, von Willebrand factor is immobilized in the reaction vessel in the presence of a substance that induces the binding of von Willebrand factor and glycoprotein Ib.

[0032] In the first, second and third methods, glyocalicin contained in a sample can be measured by adding the sample to the reaction vessel during the reaction of von Willebrand factor and glycoprotein Ib or the chimeric protein, or prior to the reaction, and detecting inhibition of the binding of von Willebrand factor and glycoprotein Ib or the chimeric protein.

5 **[0033]** Further, in the first, second and third methods, a substance that inhibits the binding of von Willebrand factor and glycoprotein Ib can be detected by adding a sample containing a substance to be detected to the reaction vessel during the reaction of von Willebrand factor and glycoprotein Ib or the chimeric protein, or prior to the reaction, and detecting inhibition of the binding of von Willebrand factor and glycoprotein Ib or the chimeric protein.

10 **[0034]** The present invention further provides a chimeric protein, which consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Ib α chain at its carboxyl terminus.

15 **[0035]** The present invention also provides a kit for measuring glyocalicin based on inhibition of a reaction of von Willebrand factor and glycoprotein Ib, which comprises von Willebrand factor and a chimeric protein that consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Ib α chain at its carboxyl terminus.

20 **[0036]** The present invention further provides a compound which is detected by any of the aforementioned methods for detecting the binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding, and has an activity for specifically inhibiting platelet aggregation involving glycoprotein Ib and von Willebrand factor in blood plasma and a molecular weight of not more than 2000.

[0037] As specific examples of the aforementioned compound, compounds having a structure represented by the formula (I), more specifically, compounds represented by the formula (II) can be mentioned. In the formulae, R¹ and R² independently represent H or Cl, and R³ represents CH₃ or H.

25

30



35

40

45

50

55



[0038] The term "chimeric protein" used in the present specification means a chimeric protein that consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Ib at its carboxyl terminus. Further, the term "glycoprotein Ib" used for the methods of the present invention may refer to glycoprotein Ib itself or the chimeric protein, or the both of them.

[0039] The term "detection" used in the present specification mainly means finding out a substance or a phenomenon, but it may also mean measurement of amount of the substance or degree of the phenomenon as a result of the finding of the substance or the phenomenon. Further, the term "measurement" mainly means measurement of an

amount of substance or a degree of phenomenon, but it may also mean finding out the substance or the phenomenon.

[0040] The present invention will be explained in detail hereinafter.

5 (1) Chimeric protein

[0041] The chimeric protein of the present invention is a protein consisting of a partial protein comprising a von Willebrand factor binding site of glycoprotein I $\beta\alpha$ chain, which is one of platelet membrane proteins of human or other mammals, bound to an Fc region of a heavy chain (H chain) of immunoglobulin molecule of mouse, human or other mammals by means of a genetic engineering technique. This chimeric protein can be produced by using cultured cells.

10 In the chimeric protein, the partial protein comprising von Willebrand factor binding site of glycoprotein I $\beta\alpha$ chain and the Fc region of the immunoglobulin molecule are bound at the carboxyl terminus of the partial protein and the amino terminus of the Fc region.

15 [0042] As an example of the partial protein of glycoprotein I $\beta\alpha$ chain, there can be mentioned a partial protein having a sequence comprising amino acid residues of from the amino terminus to the aspartic acid residue at the 319th position (amino acid numbers 1-319) of glycoprotein I $\beta\alpha$ chain molecule. However, since it is considered that von Willebrand factor binding site is a region contained in the amino acid sequences of the amino acid numbers 1-293 (V. Vincente *et al.*, *J. Biol. Chem.*, 263, 18473-18479, 1988), and in the sequence of the amino acid numbers 251-285 (V. Vicente *et al.*, *J. Biol. Chem.*, 265, 274-280, 1990), a partial protein containing at least these regions may be sufficient.

20 [0043] Further, the Fc region of immunoglobulin molecule may be derived from any animals, and may be of any subtype, and those that can be purified and/or detected with commercially available polyclonal antibodies and/or monoclonal antibodies, protein A, protein G or the like may be used. The immunoglobulin heavy chain comprises regions called VH domain, CH1 domain, hinge domain, CH2 domain and CH3 domain (and further CH4 domain in IgE) connected in this order from the amino terminus.

25 [0044] For example, the Fc region used for the chimeric protein may be a continuous sequence from the hinge domain to the CH3 domain of the above sequence. However, from the viewpoint that it should be able to be purified and/or detected with commercially available polyclonal antibodies and/or monoclonal antibodies, protein A, protein G or the like, the hinge domain is not essential, and it may partially contain a mutation such as deletion and insertion of one or more amino acid residues. Further, while the immunoglobulin may be derived from any animals including human and mouse, one derived from mouse can be used, for example. Although the subtype of the immunoglobulin may be any subtype, IgG can be used, for example. The subclass may also be any subclass, and IgG1, IgG2a and so forth can be mentioned, for example. Exemplary amino acid sequences of the chimeric protein of the present invention are shown in SEQ ID NOS: 7 and 14. In SEQ ID NOS: 7 and 14, it is presumed that 16 amino acid residues at the N-terminus constitute a signal peptide.

30 [0045] The chimeric protein of the present invention can be produced by allowing expression of a chimeric gene coding for it (chimeric protein gene) in a suitable cell. A chimeric protein gene can be prepared by obtaining a glycoprotein I $\beta\alpha$ chain gene and an immunoglobulin heavy chain gene respectively from a cDNA library, genomic library, DNA fragment or the like using genetic engineering techniques or chemically preparing them, and ligating them.

35 [0046] A glycoprotein I $\beta\alpha$ chain gene can be obtained from, for example, a cDNA library produced by using a phage vector or the like from mRNA of HEL cell, which is a human megakaryocyte cell strain, through reverse transcription PCR using suitable primer DNA designed based on a known DNA sequence of glycoprotein I $\beta\alpha$ chain gene. Further, a clone containing a glycoprotein I $\beta\alpha$ chain gene can be obtained from such a cDNA library by performing hybridization using a probe DNA designed based on the known DNA sequence. Alternatively, it can be obtained by excising it from plasmid containing a glycoprotein I $\beta\alpha$ chain gene registered at ATCC (American Type Culture Collection, pGPIb2.4, deposition number: ATCC65755) with a suitable restriction enzyme.

40 [0047] A gene of immunoglobulin heavy chain can be obtained from, for example, cDNA prepared from mRNA of mouse immunoglobulin producing hybridoma, a CDNA library produced by using a phage vector or the like through reverse transcription PCR using suitable primer DNA designed based on a known DNA sequence of the immunoglobulin heavy chain gene. Further, a clone containing a mouse immunoglobulin gene can be obtained from such a cDNA library by performing hybridization using a probe DNA designed based on the known DNA sequence.

45 [0048] A chimeric protein gene can be obtained by digesting DNA strands of a full length glycoprotein I $\beta\alpha$ chain gene or a partial sequence thereof and a full length mouse immunoglobulin heavy chain $\gamma 1$ gene or $\gamma 2a$ gene or a partial sequence thereof with a suitable restriction enzyme and then ligating them. The digestion and the ligation of the both genes may be performed so that the ligation product should code for a chimeric protein consisting of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein I $\beta\alpha$ chain at its carboxyl terminus. Further, extracellular secretion of the chimeric protein is desired, the segment for glycoprotein I $\beta\alpha$ chain may contain a signal peptide.

50 [0049] A chimeric protein gene produced as described above is expressed by using a suitable host-vector system. As the host, animal cells, insect cells and so forth can be mentioned. The vector is not particularly limited so long as it

can function as a vector in the host cell, and it is preferable to use an expression vector having a promoter suitable for the host cell. A chimeric protein can be produced by transforming the host cell with a recombinant vector obtained by inserting a chimeric protein gene into an expression vector, and culturing the transformed cell.

[0050] While a chimeric protein produced as described above may be used as it is, it can be readily purified by utilizing the Fc region of immunoglobulin molecule through affinity chromatography using immobilized protein A, protein G, anti-immunoglobulin antibodies and so forth.

(2) Method for detecting binding of von Willebrand factor and glycoprotein Ib or inhibition of this binding

[0051] The first method for detecting the binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding according to the present invention is characterized in that von Willebrand factor is immobilized in a reaction vessel in the presence of a substance inducing the binding of von Willebrand factor and glycoprotein Ib (henceforth also referred to as "binding inducing substance"), and the immobilized von Willebrand factor is allowed to react with the glycoprotein Ib.

[0052] By immobilizing von Willebrand factor in a reaction vessel in the presence of a binding inducing substance, a step of adding a binding inducing substance during the reaction of von Willebrand factor and glycoprotein Ib in a liquid phase can be omitted.

[0053] von Willebrand factor can be prepared from human blood according to the method described in H.R. Granick *et al.*, *J. Clin. Invest.*, 62, 496 (1978) or the like.

[0054] As the binding inducing substance, there can be mentioned botrocetin, ristocetin and so forth, and botrocetin is preferred.

[0055] As the reaction vessel in which von Willebrand factor is immobilized, a vessel made of synthetic resin such as polystyrene and polycarbonate or glass may be used. More specifically, a 96-well multi-well plate made of polystyrene and so forth can be mentioned. By injecting a solution containing von Willebrand factor into the aforementioned reaction vessel, von Willebrand factor can be immobilized on a wall surface of the vessel. It is also possible to immobilize collagen on a wall surface of the reaction vessel, and allow von Willebrand factor to bind to the collagen. The conditions for immobilizing von Willebrand factor or collagen to a reaction vessel are not particularly limited so long as they can be immobilized. However, when a vessel made of polystyrene is used, for example, it is preferable to use a neutral solution, preferably at pH 6.8-7.8, more preferably at about pH 7.4.

[0056] For the immobilization of von Willebrand factor, while a solution containing von Willebrand factor and a solution containing a binding inducing substance may be separately added to a reaction vessel, it is preferable to prepare a solution containing both of von Willebrand factor and a binding inducing substance, and add it into the reaction vessel, from the viewpoint of operation efficiency. Further, a reaction vessel in which von Willebrand factor is immobilized is preferably added with a bovine serum albumin solution or the like to block unbound areas on the wall surface.

[0057] After von Willebrand factor is immobilized in a reaction vessel, the reaction vessel is washed and then glycoprotein Ib is added. Upon addition of glycoprotein Ib, the binding reaction of von Willebrand factor and glycoprotein Ib is caused. This reaction is attained in a liquid phase. Subsequently, the binding of von Willebrand factor and glycoprotein Ib is detected. This detection can be performed by the method usually used for detection of the binding of von Willebrand factor and glycoprotein Ib.

[0058] The second method according to the present invention is a method wherein the binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding is detected by allowing the aforementioned chimeric protein or the chimeric protein labeled with a labeling substance to bind to von Willebrand factor immobilized in a reaction vessel, and detecting the Fc region of the immunoglobulin molecule or the labeling substance. More specifically, a solution containing von Willebrand factor is added to the reaction vessel to immobilize the von Willebrand factor on a wall surface of the reaction vessel. Then, a solution containing a chimeric protein is added to the reaction vessel to allow the chimeric protein to bind to the immobilized von Willebrand factor. This binding can be induced by the presence of a binding inducing substance in the reaction system of the von Willebrand factor and the chimeric protein. Specifically, when the aforementioned chimeric protein is allowed to bind to von Willebrand factor, or prior to the binding, a substance that induces the binding of von Willebrand factor and glycoprotein Ib is added to the reaction vessel. For example, von Willebrand factor is immobilized in the reaction vessel in the presence of a binding inducing substance in a manner similar to that of the aforementioned first method, or the binding inducing substance is added at the same time as, or at a time point around the addition of the solution containing the chimeric protein to the reaction vessel.

[0059] The chimeric protein binds to the immobilized von Willebrand factor at the von Willebrand factor binding site of glycoprotein Ib contained in the molecule. The detection of the chimeric protein bound to von Willebrand factor as described above can be performed by, for example, detecting the Fc region of the immunoglobulin molecule contained in the molecule. For the detection of the Fc region, a method usually used for immunoassay can be used.

[0060] Specifically, for example, a labeled substance that specifically binds to the Fc region such as protein A, protein G, and anti-immunoglobulin antibodies is added to the reaction vessel, and the label is detected. As the labeling

substance, there can be mentioned enzymes such as alkaline phosphatase and peroxidase, biotin, avidin, fluorescent substances such as fluorescein, compounds containing a fluorescent rare earth element such as europium and lanthanoids and so forth. Biotin or avidin is detected by further binding to them another labeling substance bound to avidin or biotin. Enzymes can be detected by adding a suitable substrate to cause an enzymatic reaction and observing visible absorbance, UV absorbance, fluorescence, luminescence etc. Furthermore, fluorescent substances and compounds having a property of emitting fluorescence can be detected based on fluorescence emitted upon irradiation with excitation light.

[0061] The chimeric protein bound to the immobilized von Willebrand factor can also be detected by using a chimeric protein labeled with a labeling substance beforehand and detecting this labeling substance. The labeling substance and the detecting method therefor may be similar to those mentioned above for use in the detection of the Fc region. When a chimeric protein labeled with a labeling substance is used, a purified chimeric protein is preferably used.

[0062] The purification of the chimeric protein can be attained by using the Fc region of the immunoglobulin molecule through affinity chromatography and so forth as described above.

[0063] The third method according to the present invention is a method wherein the binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding is detected by allowing von Willebrand factor or von Willebrand factor labeled with a labeling substance to bind to the chimeric protein immobilized in a reaction vessel, and detecting a partial structure of the von Willebrand factor or the labeling substance. More specifically, a solution containing antibodies that bind to a partial structure of the chimeric protein, preferably antibodies that binds to the immunoglobulin Fc region, protein A or protein G is added to a reaction vessel to immobilize them on a wall surface of the reaction vessel. Then, a solution containing a chimeric protein can be added to the reaction vessel to allow the chimeric protein to bind to the immobilized antibodies, protein A, protein G or the like, thereby preparing a reaction vessel on which the chimeric protein is immobilized. Alternatively, a chimeric protein may be directly immobilized in a reaction vessel. Subsequently, a solution containing von Willebrand factor or von Willebrand factor labeled with a labeling substance is added to the reaction vessel to allow the von Willebrand factor to bind to the immobilized chimeric protein. This binding can be induced by adding a binding inducing substance to a reaction system of the von Willebrand factor and the chimeric protein. Specifically, when the aforementioned chimeric protein is allowed to bind to the von Willebrand factor, or prior to the binding, a substance that induces the binding of von Willebrand factor and glycoprotein Ib is added to reaction vessel. For example, a binding inducing substance is added at the same time as, or at a time point around the addition of the solution containing von Willebrand factor or von Willebrand factor labeled with a labeling substance to the reaction mixture.

[0064] The von Willebrand factor binds to the immobilized chimeric protein. The von Willebrand factor that binds to the chimeric protein as described above can be detected, for example, by using antibodies that bind to von Willebrand factor. For the detection of the antibodies bound to the von Willebrand factor, a method usually used for immunoassay can be used. Specifically, for example, there can be mentioned methods utilizing beforehand labeling of the antibodies that bind to von Willebrand factor with an enzyme such as alkaline phosphatase and peroxidase, biotin, avidin, fluorescent substance such as fluorescein, compound containing a fluorescent rare earth element such as europium and lanthanoids or the like. Biotin or avidin is detected by further binding to them another labeling substance bound to avidin or biotin. Enzymes can be detected by adding a suitable substrate to cause an enzymatic reaction and observing visible absorbance, UV absorbance, fluorescence, luminescence etc. Furthermore, fluorescent substances and compounds having a property of emitting fluorescence can be detected by fluorescence emitted upon irradiation with excitation light.

[0065] The von Willebrand factor bound to the immobilized chimeric protein can also be detected by using von Willebrand factor labeled beforehand with a labeling substance and detecting this labeling substance. The labeling substance and the detecting method therefor may be similar to those used for the detection of the aforementioned antibodies that bind to von Willebrand factor.

[0066] In the aforementioned first, second and third methods, inhibition of the binding of von Willebrand factor and glycoprotein Ib can be detected by comparing a case where a substance inhibiting the binding of von Willebrand factor and glycoprotein Ib (henceforth also referred to as "binding inhibition substance") is added to a reaction vessel at substantially the same time as the addition of glycoprotein Ib (or a chimeric protein) to the reaction vessel or prior to the addition of glycoprotein Ib and a case where the inhibition substance is not added for the binding of von Willebrand factor and glycoprotein Ib.

[0067] Further, in the aforementioned first, second and third methods, a substance inhibiting the binding of von Willebrand factor and glycoprotein Ib can be detected by adding a sample containing a substance to be detected to the reaction vessel during the reaction of von Willebrand factor and glycoprotein Ib or prior to the reaction and detecting inhibition of the binding of von Willebrand factor and glycoprotein Ib. If a standard curve that represents the relation between amount of an inhibition substance and binding of von Willebrand factor and glycoprotein Ib is prepared, the inhibition substance of an unknown amount can be quantified.

[0068] No low molecular weight compound has been reported so far, which inhibits the binding of von Willebrand

factor and glycoprotein Ib and has antithrombotic activity. The methods of the present invention are extremely simpler compared with the conventional methods, and are also useful for search of such a low molecular compound as mentioned above.

5 (3) Method and kit for measurement of glycocalicin

[0069] In the aforementioned first, second and third methods, glycocalicin can be measured by adding a sample containing glycocalicin to the reaction vessel during the reaction of von Willebrand factor and glycoprotein Ib or prior to the reaction and detecting inhibition of the binding of von Willebrand factor and glycoprotein Ib. If a standard curve that represents the relation between glycocalicin concentration and the binding of von Willebrand factor and glycoprotein Ib is prepared, concentration of glycocalicin in an unknown amount can be measured.

[0070] If von Willebrand factor and the chimeric protein are prepared as a kit, the measurement of glycocalicin according to the present invention can conveniently be performed. As such a kit, there can be specifically exemplified a kit comprising von Willebrand factor, a chimeric protein, a binding inducing substance, glycocalicin of a known amount, anti-immunoglobulin antibodies labeled with alkaline phosphatase or the like, a reagent for detecting the label and a washing buffer. As another embodiment, there can be exemplified a kit comprising von Willebrand factor, a chimeric protein labeled with a labeling substance, a binding inducing substance, glycocalicin of a known amount, a reagent for detecting the label and a washing buffer.

20 (4) Low molecular weight true inhibition substance for binding of von Willebrand factor and glycoprotein Ib

[0071] By using the method of the present invention for detecting the inhibition of the binding of von Willebrand factor and glycoprotein Ib described in the above (2), a low molecular weight true inhibition substance for binding of von Willebrand factor and glycoprotein Ib can be searched (screened). The term "true inhibition substance" used herein means a substance that specifically inhibits platelet aggregation in plasma involving von Willebrand factor and glycoprotein Ib. A substance that inhibits the binding of von Willebrand factor and glycoprotein Ib in a non-specific manner is not a true inhibition substance, even though it may inhibit the binding of von Willebrand factor and glycoprotein Ib, like substances that generally change structures of proteins such as protein denaturing substances and detergents or substances that non-specifically bind to proteins.

[0072] A true inhibition substance can be distinguished by measuring inhibitory activity for von Willebrand factor and glycoprotein Ib dependent platelet aggregation in plasma using ristocetin or botrocetin and inhibitory activity for von Willebrand factor and glycoprotein Ib non-dependent platelet aggregation using collagen or adenosine diphosphate (ADP), and comparing them. That is, a compounds which inhibit von Willebrand factor and glycoprotein Ib dependent platelet aggregation (for example, ristocetin-induced platelet aggregation), and does not substantially inhibit von Willebrand factor and glycoprotein Ib non-dependent platelet aggregation (for example, platelet aggregation induced by collagen or ADP) at the same concentration is a true inhibition substance for the binding of von Willebrand factor and glycoprotein Ib.

[0073] The inhibition substance of the present invention preferably inhibit von Willebrand factor and glycoprotein Ib dependent platelet aggregation at a level of 80% or more, more preferably 90% or more, at a concentration of, for example, 1 mM. Further, if inhibition for von Willebrand factor and a glycoprotein Ib non-dependent platelet aggregation is 30% or less, preferably 25% or less, it can be regarded that there is not substantial inhibition.

[0074] The term "low molecular weight" preferably means a molecular weight of 2000 or less, more preferably 1000 or less. Further, the inhibition substance of the present invention is preferably one that can exert the activity even if it is not a polymer.

[0075] Specific examples of low molecular weight antithrombotic substances screened by the method of the present invention include the compounds of the aforementioned structures, more specifically those compounds mentioned below, which were designated as K17427A, K17427B, K17427C and K17427D. These compounds were found in an actinomycete belonging to the genus *Couchioplanes* (*Couchioplanes* sp. AJ9553 (FERM BP-6612)) as substances that had activity of markedly inhibiting the binding of von Willebrand factor and glycoprotein Ib. The physicochemical properties of these compounds and an exemplary method for producing them will be explained below.

(1) Physicochemical properties of K17427A, K17427B, K17427C and K17427D

[0076]

55 (i) Physicochemical properties of K17427A

Appearance: yellow amorphous solid

Molecular formula: C₄₄H₄₄O₁₄Cl₂

Mass spectrometry (high resolution FAB-MS)	
Found:	866.2117 (M) ⁺
Calcd.:	866.2108

Specific rotation: $[\alpha]_D^{24}$: -60° (c 0.09, THF)Ultraviolet absorption spectrum: λ_{max} (ϵ) 235 (57000), 276 (59500), 427 (25000)¹H-NMR spectrum (400 MHz, CD₃CO₂D) δ : 7.64 (2H, s), 6.04 (2H, s), 5.38 (2H, s), 3.45 (8H, s), 2.05 (2H, m), 1.28 (6H, d, J=6.8Hz), 1.04 (6H, d, J=6.6Hz), 0.38 (6H, d, J=6.3Hz)¹³C-NMR spectrum (100 MHz, CD₃CO₂D) δ : 205.9 (s), 173.2 (s), 171.8 (s), 162.1 (s), 154.6 (s), 135.5 (d), 134.8 (s), 131.4 (s), 120.8 (s), 120.2 (s), 114.5 (d), 113.1 (s), 111.3 (s), 94.2 (d), 77.6 (s), 55.4 (q), 48.1 (d), 44.3 (d), 35.0 (d), 16.3 (q), 6.7 (q)

Solubility: easily soluble in dimethyl sulfoxide, pyridine and acetic acid, hardly soluble in water Structural formula: structure represented by the aforementioned formula (II)

(ii) Physicochemical properties of K17427B

Appearance: yellow amorphous solid

Molecular formula: C₄₃H₄₂O₁₄Cl₂

Mass spectrometry (high resolution FAB-MS)	
Found:	852.1997 (M) ⁺
Calcd.:	852.1952

Specific rotation: $[\alpha]_D^{25}$: -61° (c 0.13, THF)Ultraviolet absorption spectrum (methanol): $\lambda_{\text{max}}(\epsilon)$ 235 (41000), 273 (43000), 434 (18500)¹H-NMR spectrum (400MHz, CD₃CO₂D) δ : 7.81 (2H, s), 6.17 (1H, s), 6.14 (1H, s), 5.54 (1H, s), 5.50 (1H, s), 3.62 (3H, s), 3.58 (3H, s), 3.53 (1H, q, J=7.0Hz), 3.20 (1H, d, J=18Hz), 3.08 (1H, d, J=18Hz), 1.20 (3H, d, J=7.6Hz), 1.17 (3H, d, J=6.7Hz), 1.04 (3H, d, J=6.7Hz), 0.97 (3H, d, J=6.7Hz), 0.52 (3H, d, J=7.0Hz)Solubility: easily soluble in dimethyl sulfoxide, pyridine and acetic acid, hardly soluble in water Structural formula: structure represented by the aforementioned formula (I) wherein R¹ = R² = Cl and R³ = H

(iii) Physicochemical properties of K17427C

Appearance: yellow amorphous solid

Molecular weight (ESI-MS): 799 (M+H)⁺Ultraviolet absorption spectrum: λ_{max} 234, 281, 418¹H-NMR spectrum (400 MHz, CD₃OD) δ : 7.59 (2H, d, J=8.4Hz), 7.25 (2H, d, J=8.4Hz), 7.14 (2H, s), 6.05 (2H, s), 5.37 (2H, brs), 3.59 (6H, s), 3.46 (2H, br), 2.12 (2H, m), 1.38 (6H, d, J=5.2Hz), 1.15 (6H, d, J=6.8Hz), 0.64 (6H, br)Structural formula: structure represented by the aforementioned formula (I) wherein R¹ = R² = H and R³ = CH₃

(iv) Physicochemical properties of K17427D

Appearance: yellow amorphous solid

Molecular weight (ESI-MS): 833 (M+H)⁺Ultraviolet absorption spectrum: λ_{max} 234, 276, 423

¹H-NMR spectrum (400 MHz, CD₃OD)δ: 7.77 (2H, s), 7.59 (1H, d, J=8.4Hz), 7.26 (1H, d, J=8.4Hz), 7.15 (1H, s), 6.09 (1H, s), 6.08 (1H, s), 5.46 (1H, s), 5.37 (1H, brs), 3.61 (3H, s), 3.54 (4H, s), 3.42 (1H, q, J=7.0Hz), 2.12 (2H, m), 1.39 (3H, d, J=6.8Hz), 1.20 (6H, m), 0.63 (3H, br), 0.50 (3H, d, J=7.0Hz)

Structural formula: structure represented by the aforementioned formula (I) wherein R¹ = Cl, R² = H and R³ = CH₃

5 (2) Method for producing K17427A, K17427B, K17427C and K17427D

[0077] The inhibition substances for the binding of von Willebrand factor and glycoprotein Ib of the present invention, K17427A, B, C and D (henceforth referred to simply as "inhibition substances") can be produced by, for example, culturing an actinomycete belonging the genus *Couchioplanes*, for example, *Couchioplanes* sp. AJ9553 (FERM BP-6612) using a liquid or solid nutrient medium containing an assimilable carbon source and nitrogen source. As the carbon source of the nutrient medium, carbohydrates such as glucose, sucrose and starch, glycerol and so forth can be preferably used. As the nitrogen source, naturally occurring substances such as yeast extract, peptone, corn steep powder, soybean flour and cotton seed flour (Pharmamedia), amino acids, inorganic nitrogen-containing compounds such as ammonium sulfate and urea and so forth can be used.

[0078] The culture for the production of the inhibition substances may be performed as culture with shaking or standing culture using a test tube, flask containing the aforementioned nutrient medium or the like, aeration culture with stirring using a jar fermenter, tank containing the aforementioned nutrient medium or the like and so forth. The culture can be performed usually in the range of 20°C to 40°C, preferably 25°C to 37°C.

[0079] Extraction of the inhibition substances from culture broth after completion of the culture can be performed by, for example, extraction with a suitable solvent, adsorption of the inhibition substances on an adsorption resin or the like and subsequent elution with a suitable solvent. Further, purification of the inhibition substances can be performed by combination of techniques such as solvent extraction, chromatography or reversed phase chromatography and so forth utilizing adsorption resin, activated charcoal, ion exchange resin, silica gel etc.

[0080] Specifically, for example, cells of *Couchioplanes* sp. AJ9553 (FERM BP-6612) strain are extracted with acetone, acetone is evaporated from the extract, and the residue is suspended in water. The aqueous suspension is adjusted to pH 2, and then ethyl acetate is added to extract it. The ethyl acetate layer is concentrated under reduced pressure, and the obtained residue is fractionated by anion exchange chromatography. For example, the residue can be dissolved in water-containing methanol, adsorbed on a column filled with DIA ION HP-20 (Mitsubishi Chemical), and eluted with methanol. Then, an inhibition substance is obtained by fractionation of the eluate by HPLC using an ODS column, or fractionation by silica gel TLC. To which one of the compounds mentioned above the obtained inhibition substance corresponds can be determined by examining the aforementioned physicochemical properties.

35 Brief Explanation of the Drawings

[0081]

Fig. 1 outlines the construction of GPIb-mIgG1Fc expression system.

40 Fig. 2 outlines the construction of GPIb-mIgG2aFc expression system.

Fig. 3 shows binding amount of immobilized von Willebrand factor and a chimeric protein plotted against amount of botrocetin (ELISA).

Fig. 4 shows activity of inhibition substance for the binding of von Willebrand factor and a chimeric protein (ELISA).

45 Fig. 5 shows activity of inhibition substance for the binding of von Willebrand factor and a chimeric protein (Eu-labeling method).

Fig. 6 shows exemplary quantification of glycocalcin in human plasma (ELISA).

Fig. 7 shows exemplary quantification of glycocalcin in human plasma (Eu-labeling method).

Fig. 8 shows activity of inhibition substance for the binding of von Willebrand factor and a chimeric protein (method utilizing presence of botrocetin in liquid phase).

50 Fig. 9 shows activity of inhibition substance for the binding of von Willebrand factor and a chimeric protein (method utilizing immobilized chimeric protein).

Fig. 10 shows activity of inhibition substances K17427A, B, C and D for the binding of von Willebrand factor and a chimeric protein (Eu-labeling method).

55 Fig. 11 shows activity of inhibition substances K17427A, B, C and D for the binding of von Willebrand factor and a chimeric protein (¹²⁵I-labeling method).

Fig. 12 shows inhibitory activity of K17427A for ristocetin induced-platelet aggregation, and ADP- and collagen-induced aggregation.

Best Mode for Carrying out the Invention

[0082] The present invention will be explained more specifically in to the following examples.

5 Example 1: Preparation of chimeric protein gene

(1) Cloning of glycoprotein I α chain gene

[0083] Cloning of human glycoprotein I α chain gene was attained by constructing a cDNA library from human erythroleukemia cells (HEL) according to the method described in Molecular Cloning (Sambrook, J., Fritsch, E.F., Maniatis, T., Molecular Cloning, Cold Spring Harbor Laboratory Press (1989)). That is, human erythroleukemia cells were stimulated by culturing them in a medium containing 160 nM of a phorbol ester (phorbol-12-myristate-13-acetate: PMA) for 48 hours, and then the medium was removed. A guanidinium thiocyanate buffer (4.0 M guanidinium thiocyanate, 0.1 M Tris-HCl (pH 7.5), 1% 2-mercaptoethanol) was added to the cells to suspend the cells in the buffer. The cell suspension was subjected to disruption treatment by using a Polytron homogenizer (produced by Brinkmann).

[0084] Laurylsarcosinate (sodium laurylsarcosinate) was added to the disrupted cell suspension at a final concentration of 0.5%. This solution was centrifuged at 5000 x g for 10 minutes to remove the precipitates. The centrifugation supernatant was overlaid on cesium chloride/EDTA solution (5.7 M CsCl, 0.01 M EDTA, pH 7.5) contained in an ultracentrifugation tube and subjected to ultracentrifugation at 100000 x g for 20 hours. The precipitated RNA was collected and purified by ethanol precipitation to obtain total RNA.

[0085] The obtained total RNA was loaded on an oligo-dT cellulose column to obtain mRNA. From 10 μ g of this mRNA, single-stranded DNA was prepared by using random hexamer oligo DNA as a primer and a reverse transcriptase, and then double-stranded cDNA was prepared by using a DNA polymerase. An EcoRI adapter was ligated to this cDNA by using T4 DNA ligase. The cDNA to which the adapter was ligated was subjected to a phosphorylation treatment using T4 polynucleotide kinase, and purified by using a gel filtration column. A λ gt10 arm prepared so that it could be inserted into an EcoRI restriction site (produced by Stratagene) was ligated to this DNA using T4 DNA ligase. This recombinant DNA was packaged in phage to obtain a cDNA library.

[0086] *Escherichia coli* NM514 was infected with this phage. Plaque hybridization was performed for the produced phage plaques by using oligo DNA (SEQ ID NO: 1) end-labeled with a radioisotope (32 P) as a probe. That is, the produced phage plaques were transferred to a nitrocellulose filter, and DNA was denatured with an alkaline denaturation solution (0.5 M sodium hydroxide, 1.5 M sodium chloride). The filter was neutralized with a neutralization solution (0.5 M Tris-HCl, pH 7.0, 1.5 M sodium chloride), and heated at 80°C for 2 hours to immobilize the DNA on the filter. Synthesized DNA (chemically synthesized by using a DNA synthesizer Model 380A produced by Perkin-Elmer Applied Biosystems) was labeled at the 5' end of the DNA with γ - 32 P-ATP with the aid of T4 DNA kinase (produced by Takara Shuzo), and used as probe DNA. The nucleotide sequence of the aforementioned oligo DNA was designed based on the nucleotide sequence of a known human glycoprotein I α chain gene (J.A. Lopez *et al.*, *Proc. Natl. Acad. Sci. USA*, 84, 5615-5619 (1987)).

[0087] The nitrocellulose filter (diameter: 132 mm) on which phage plaque DNA was transferred was immersed in 4 ml of a hybridization buffer (0.9 M sodium chloride, 0.09 M sodium citrate (pH 7.0), 0.5% sodium laurylsulfate, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 0.1% bovine serum albumin, 100 μ g/ml heat-denatured salmon sperm DNA) containing the probe corresponding to 1×10^6 cpm (count per minute) per one filter, and allowed to hybridize at 42°C for 16 hours. The filter was washed three times with 1 x SSC (0.875% sodium chloride, 0.441% sodium citrate, pH 7.0) and 0.1% sodium laurylsulfate solution at 37°C for 30 minutes to remove the probe non-specifically adsorbed on the filter. After the filter was dried, radioautography was performed by using an X-ray film. As a result, four strains of positive clones were obtained.

[0088] The phage was isolated from each positive clone, and *Escherichia coli* NM514 was infected with the isolated phage and proliferated. Then, phage DNA from each clone was purified by cesium chloride density gradient ultracentrifugation. This phage DNA was digested with a restriction enzyme EcoRI, and DNA was purified by agarose electrophoresis. This purified DNA was inserted into the EcoRI site of pBluescriptSK-(produced by Stratagene) and used for transformation of the *Escherichia coli* XL1blue (produced by Stratagene) to obtain a transformant. Plasmid was prepared from the transformant by the alkali SDS method, and the nucleotide sequence of the plasmid DNA was determined by the dideoxy method using a DNA sequencer Model 377 produced by Perkin-Elmer Applied Biosystems according to the protocol attached to the instrument. It was confirmed that one strain among the obtained positive clones contained cDNA of 2.4 kb, and it was the clone having the full length of human glycoprotein I α gene reported by J.A. Lopez *et al.* (*Proc. Natl. Acad. Sci. USA*, Vol. 84, pp.5615-5619 (1987)). This plasmid was designated as pBluescriptGPIbAlpha.

(2) Cloning of gene coding for Fc region of immunoglobulin (γ 1 origin)

[0089] The gene for the Fc region of mouse immunoglobulin γ 1 was obtained by extracting total RNA from a mouse hybridoma cell strain MB40.3 and performing reverse transcription PCR. That is, from 10 ml of culture broth of MB40.3 cells, the cells were collected by centrifugation, and the cells were lysed with ISOGEN (1 ml, produced by Nippon Gene). The lysate was subjected to syringing using an injection needle of 18G. The lysate was left for 5 minutes, then added with 200 μ l of chloroform and mixed. The mixture was left stand for 2 minutes and then centrifuged (15000 rpm, 15 minutes) to recover an aqueous phase. The aqueous phase was added with 500 μ l of 2-propanol, mixed, left stand for 5 minutes and centrifuged (15000 rpm, 15 minutes) to precipitate the total RNA. The total RNA was washed with 75% ethanol and dissolved in 100 μ l of sterilized water.

[0090] cDNA was prepared by using 3 μ g (20 μ l) of MB40.3 cell total RNA prepared as described above as a template and using random primers and reverse transcriptase (Superscript II produced by GIBCO). The cDNA was amplified by PCR using the primers Of SEQ ID NOS: 2 and 3, digested with HindIII and BamHI, purified by agarose gel electrophoresis, and ligated to pGEM-3Zf (produced by Promega) digested with HindIII and BamHI. *Escherichia coli* XL1blue (produced by Stratagene) was transformed with the obtained recombinant DNA. One of the obtained transformants was cultured. Plasmid was prepared by the alkali SDS method, and the nucleotide sequence thereof was determined by the dideoxy method using a DNA sequencer Model 377 produced by Perkin-Elmer Applied Biosystems according to the protocol attached to the instrument. The obtained nucleotide sequence of the gene fragment for the Fc region of mouse immunoglobulin γ 1 is shown in SEQ ID NO: 4. This plasmid was designated as pGEMmlgG1Fc.

(3) Preparation of plasmid expressing chimeric protein (GPIb-mlgG1Fc)

[0091] A chimeric protein comprising the human glycoprotein Ib gene and the Fc region of mouse immunoglobulin γ 1 obtained as described above, which were fused together, was prepared as follows.

[0092] First, the plasmid pBluescriptGPIAlpha containing the glycoprotein Ib α chain gene was digested with restriction enzymes EcoRI and XbaI, and separated by agarose gel electrophoresis to recover DNA of about 1000 bp, which corresponded to the N-terminus region of glycoprotein Ib α chain gene. This was inserted into the EcoRI-XbaI site of pBluescriptSK- (produced by Stratagene) to prepare plasmid pBluescriptGPIbEX.

[0093] Separately, the plasmid pGEMmlgG1Fc containing the partial gene of mouse immunoglobulin γ 1 obtained as described above was digested with a restriction enzyme XbaI and separated by agarose gel electrophoresis to recover the IgG1Fc gene of 700 bp. This DNA was ligated to pBluescriptGPIbEX digested with a restriction enzyme XbaI and subjected to CIAP treatment to obtain plasmid pBluescriptGPIbIgG1FcFH. The protein encoded by this gene was designated as GPIb-mlgG1Fc, of which gene sequence and amino acid sequence are shown in SEQ ID NOS: 6 and 7, respectively. In SEQ ID NO: 6, it is presumed that the 16 amino acid residues of the N-terminus constitute a signal peptide.

[0094] Further, pBluescriptGPIbIgG1FcFH was digested with a restriction enzyme Xhol, and DNA coding for GPIbFcFH was separated by agarose gel electrophoresis. This DNA was inserted into the Xhol site of an expression vector for animal cells pSD(X) to obtain an expression vector pSDGPIbIgG1FcFH, in which the GPIb gene was inserted downstream from a promoter. The outline of the aforementioned procedure is shown in Fig. 1. *Escherichia coli* XL1blue (*Escherichia coli* AJ13434) harboring the plasmid pSDGPIbIgG1FcFH was deposited at the National Institute of Biotechnology and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry on April 2, 1998, and given an accession number of FERM P-16749. This was transferred to an international deposit under the provision of the Budapest Treaty on January 11, 1999, and given an accession number of FERM BP-6619.

(4) Cloning of gene coding for Fc region of immunoglobulin (γ 2a origin)

[0095] The gene of the Fc region of mouse immunoglobulin γ 2a was obtained by extracting total RNA from a mouse hybridoma cell strain W6/32 and performing reverse transcription PCR. That is, from 10 ml of culture broth of W6/32 cells, the cells were collected by centrifugation, and the cells were lysed with ISOGEN (1 ml, produced by Nippon Gene). The lysate was subjected to syringing using an injection needle of 18G. The lysate was left for 5 minutes, then added with 200 μ l of chloroform and mixed. The mixture was left stand for 2 minutes and then centrifuged (15000 rpm, 15 minutes) to recover an aqueous phase. The aqueous phase was added with 500 μ l of 2-propanol, mixed, left stand for 5 minutes and then centrifuged (15000 rpm, 15 minutes) to precipitate the total RNA. The total RNA was washed with 75% ethanol and dissolved in 100 μ l of sterilized water.

[0096] cDNA was prepared by using 3 μ g (20 μ l) of the W6/32 cell total RNA prepared as described above as a template and using random primers and reverse transcriptase (Superscript II produced by GIBCO). The cDNA was amplified by PCR using primers having nucleotide sequences of SEQ ID NOS: 8 and 9, digested with HindIII and BamHI,

purified by agarose gel electrophoresis, and ligated to pGEM-3Zf (produced by Promega) digested with *Hind*III and *Bam*HI. *Escherichia coli* XLIIblue (produced by Stratagene) was transformed with the obtained recombinant DNA. One of the obtained transformants was cultured. Plasmid was prepared by the alkali SDS method and the nucleotide sequence thereof was determined by the dideoxy method using a DNA sequencer Model 377 produced by Perkin-
5 Elmer Applied Biosystems according to the protocol attached to the instrument. The obtained nucleotide sequence of the gene fragment for the Fc region of mouse immunoglobulin γ 2a is shown in SEQ ID NO: 10. This plasmid was designated as pGEMmlgG2aFc.

(5) Preparation of plasmid expressing chimeric protein (GPIb-mlgG2aFc)

[0097] A chimeric protein gene comprising the human glycoprotein Ib gene and the Fc region of mouse immunoglobulin γ 1 obtained as described above and fused together was prepared as follows.
 [0098] First, the plasmid pBluescriptGPIAlpha containing the glycoprotein Ib α chain gene was digested with restriction enzymes *Eco*RI and *Xba*I, and separated by agarose gel electrophoresis to obtain a *Kpn*I-*Xba*I DNA fragment containing the sequence of glycoprotein Ib gene for the sequence of from the N-terminus to the 319th aspartic acid.
 [0099] Further a gene fragment of the Fc region of mouse immunoglobulin γ 2a having an *Xho*I site at the 5' end side and an *Xba*I site at the 3' end side was produced by PCR (annealing temperature: 55°C, 30 cycles) using the plasmid pGEMmlgG2aFc containing the partial gene of mouse immunoglobulin γ 2a obtained as described above, two kinds of synthetic primers having the nucleotide sequences shown in SEQ ID NOS: 9 and 12 and PFU (produced by Stratagene). This gene fragment was digested with *Xba*I and *Xho*I, then purified by agarose gel electrophoresis and ligated to pBluescriptSK-digested with *Xba*I and *Xho*I. *Escherichia coli* XLIIblue (produced by Stratagene) was transformed with the obtained recombinant plasmid. Plasmid was prepared from the obtained transformant by the alkali SDS method, and the nucleotide sequence thereof was determined by the dideoxy method using a DNA sequencer Model 377 produced by Perkin-Elmer Applied Biosystems according to the protocol attached to the instrument. As a result, it was confirmed to have a nucleotide sequence corresponding to the nucleotide sequence shown in SEQ ID NO: 10 of which 6 nucleotides at the 5' end was replaced with TCTAGAC and 6 nucleotides at the 3' end was eliminated. This plasmid was designated as pBluescriptmlgG2a. This plasmid was digested with *Xba*I and *Xho*I, and purified by agarose gel electrophoresis to obtain a *Xba*-*Xho* fragment of the Fc region gene of mouse immunoglobulin γ 2a.
 [0100] The *Kpn*I-*Xba*I fragment of human glycoprotein Ib gene and the *Xba*-*Xho* fragment of Fc region gene of mouse immunoglobulin γ 2a obtained as described above were ligated to pBluescriptSK- digested with *Kpn*I and *Xho*I, and *Escherichia coli* XLIIblue (produced by Stratagene) was transformed with the obtained recombinant plasmid. One of the obtained transformants was cultured, and plasmid was prepared by the alkali SDS method to obtain plasmid containing a gene coding for a protein (chimeric protein) comprising the N-terminus side region of glycoprotein Ib (amino acid numbers 1-319, including a signal peptide) and the Fc region of mouse immunoglobulin γ 2a bound together (SEQ ID NO: 13). This plasmid was designated as pBluescriptGPIbFc2a, and the encoded chimeric protein corresponding to the gene was especially designated as GPIb-mlgG2aFc, of which amino acid sequence was shown in SEQ ID NO: 14. In SEQ ID NO: 14, it is presumed that 16 amino acid residues of the N-terminus constitute a signal peptide. *Escherichia coli* XLIIblue (*Escherichia coli* AJ13432) harboring the plasmid pBluescriptGPIbFc2a was deposited at the National Institut of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry on March 19, 1998, and given an accession number of FERM P-16719. Then, it was transferred to an international deposit under the provisions of the Budapest Treaty on January 11, 1999, and given an accession number of FERM BP-6618.
 [0101] pBluescriptGPIbFc2a was digested with *Xho*I, and purified by agarose electrophoresis. This *Xho*I fragment containing a gene of the chimeric protein was ligated to the *Xho* site of the same animal cell expression vector pSD(x) as the above (3) to obtain plasmid pSDGPIbFc2a. Further, pGPIbFcbluescript was digested with *Eco*RI and *Xho*I, and the *Eco*RI-*Xho* fragment containing the chimeric protein gene was inserted into the *Eco*RI-*Xho* site of expression vector pMikNeo(+) for animal cells (kindly provided by Dr. K. Maruyama, the Institute of Medical Science, the University of Tokyo) having SR α promoter (K. Maruyama and Y. Takebe *et al.*, *Medical Immunology*, 20, 27-32, 1990) to obtain plasmid pMikGPIbFc. The outline of the procedure used for obtaining pMikGPIbFC is shown in Fig. 2.

Example 2: Production of chimeric protein (GPIb-mlgG1Fc) using animal cells

[0102] Cells producing the chimeric protein were produced as follows. CHOdhfr cells were cultured by using D-MEM medium (10 ml, produced by GIBCO) containing 10% fetal bovine serum at 37°C under 5% CO₂ at a density of 5 x 10⁵ cells per 10-cm dish. The cells were transfected with pSDGPIbIgG1Fc prepared as described in Example 1 (3). The transfection was performed by using calcium phosphate as described below. That is, about 10 μ g per 10-cm dish of pSDGPIbIgG1Fc was added to 0.5 ml of BES buffer (pH 6.96) containing 0.125 M calcium chloride, uniformly added dropwise to a dish, and incubated overnight at 35°C under 3% CO₂. Then, the dish was washed twice with PBS, and

further incubated in α -MEM medium not containing nucleic acid at 37°C for about 24 hours under 5% CO₂. The cells transfected as described above were further cultured in α -MEM medium not containing nucleic acids, but containing 0.05 μ M methotrexate (MTX) and 10% fetal bovine serum to obtain chimeric protein producing cells.

[0103] The chimeric protein producing cells obtained as described above were cultured in an F175 cell culture flask containing α -MEM medium not containing nucleic acid, but containing 0.05 μ M methotrexate (MTX) and 10% fetal bovine serum, until about 60% confluent. Then, the medium was exchanged with a serum-free medium, ASF104 medium (produced by Ajinomoto), containing 0.05 μ M methotrexate (MTX), and the culture supernatant was collected four days later.

10 Example 3: Production of chimeric protein (GPIb-mlgG2aFc) using animal cells

[0104] Cells producing the chimeric protein were produced as follows. CHOK1 cells were cultured by using D-MEM medium (10 ml, produced by GIBCO) containing 10% fetal bovine serum at 37°C under 5% CO₂ at a density of 5×10^5 cells per 10-cm dish. The cells were transfected with pMikGPIbFc prepared in Example 1. The transfection was performed by the calcium phosphate method as described below. That is, about 10 μ g per 10-cm dish of pMikGPIbFc was added to 0.5 ml of BES buffer (pH 6.96) containing 0.125 M calcium chloride, uniformly added dropwise to a dish, and incubated overnight at 35°C under 3% CO₂. Then, the dish was washed twice with PBS, and further incubated in D-MEM medium at 37°C for about 24 hours under 5% CO₂. The cells transfected as described above were further cultured in D-MEM medium containing G418 (850 μ g/ml) and 10% fetal bovine serum to obtain chimeric protein producing cells, which were G418 resistant cells.

[0105] The chimeric protein producing cells obtained as described above were cultured in an F175 cell culture flask containing D-MEM medium containing G418 (800 μ g/ml) and 10% fetal bovine serum until about 60% confluent. Then, the medium was exchanged with a serum-free medium, ASF104 medium (produced by Ajinomoto), containing G418 (800 μ g/ml), and the culture supernatant was collected four days later.

[0106] The collected culture supernatant was centrifuged to remove the solid, and then 160 ml of the supernatant was passed through a Protein A Hitrap (1 ml, produced by Pharmacia) column washed with 20 mM phosphate buffer (pH 7.0) so that the chimeric protein should be adsorbed on the column. The column was sufficiently washed with 20 mM phosphate buffer (pH 7.0), and then eluted with 0.1 M citrate buffer (pH 4.5). The elution of the chimeric protein was performed with detection by a UV monitor at 280 nm, and chimeric protein eluted fractions were immediately neutralized by adding 1 M Tris-HCl buffer (pH 8.5). As a result of SDS electrophoresis, the chimeric protein obtained as described above was found to be a protein having a molecular weight of about 80 kDa as a reduced form and a molecular weight about twice as much as that of the reduced form as non-reduced form.

Example 4 Detection of binding of chimeric protein to immobilized mixture of von Willebrand factor and botrocetin

35 (1) Detection of binding of chimeric protein by ELISA using anti-mouse IgG-Fc antibodies

[0107] Botrocetin was obtained from 1 g of lyophilized product of crude venom of *Botrops jararaca* (produced by Sigma) by purification according to the method reported by Read (M.S. Read *et al.*, *Proc. Natl. Acad. Sci. USA.*, 75, 4514-4518, 1978).

[0108] Immobilization of a mixed solution of von Willebrand factor and botrocetin on a 96-well multititer plate was attained as follows. First, a physiological saline solution of von Willebrand factor (250 μ g/ml) and a physiological saline solution of botrocetin (500 μ g/ml), which were prepared in a conventional manner, were appropriately diluted, and mixed at the concentration ratios shown in Fig. 2. Then, 50 μ l of each mixture was added to each well of a 96-well multititer plate (Maxisorp, produced by Nunc). The plate was left stand overnight at 4°C, and then each well was washed once with a physiological Tris buffer (150 μ l, 20 mM Tris-HCl (pH 7.4), 0.15 M sodium chloride; Tris buffered saline, referred to as "TBS" hereinafter). Then, each well was added with 100 μ l of TBS containing 10% BSA (bovine serum albumin), left stand for about 3 hours, and washed 3 times with TBS to obtain a von Willebrand factor immobilized plate.

[0109] Each well of the plate on which von Willebrand factor was immobilized in the presence of botrocetin as described above was added with 25 μ l of TBS containing 1% BSA and 25 μ l of a solution prepared by diluting 8 times the culture supernatant of the chimeric protein (GPIb-mlgG1Fc) producing cells obtained by using the serum free medium with TBS containing 1% BSA, incubated at room temperature for 1 hour, and washed 3 times with TBS (150 μ l) containing 0.05% Tween-20. Anti-mouse IgG-Fc goat polyclonal antibodies (Catalog No. 55482, produced by Organon Teknika) were biotinylated by using Biotin Labeling Kit (Catalog No. 1418165, produced by Boehringer Mannheim) according to the protocol attached to the kit. 50 μ l of 0.1% BSA/TBA solution containing about 2 μ g/ml of the above biotinylated anti-mouse IgG-Fc antibodies was added to each well of the plate, and incubated at room temperature for 1 hour. Further, each well was washed 3 times with TBS (150 μ l) containing 0.05% Tween-20, added with 50 μ l of a solution of the reagent (mixture of biotinylated alkaline phosphatase and streptavidin) contained in VECTASTAIN ABC kit

(kit for biotin detection, Alkaline phosphatase standard, Catalog No. AK-5000, produced by Vector Laboratories), which solution was prepared in 0.1% BSA/TBS at 1/5 concentration of that used in the method specified in the manual, and incubated at room temperature for 1 hour. Each well was washed 5 times with TBS (150 μ l) containing 0.05% Tween-20, and added with 100 μ l of 100 mM NaHCO₃ solution containing 10 mM MgCl₂, in which p-nitrophenylphosphate was dissolved at 1 mg/ml, to carry out the color development reaction for about 1 hour. After the color development, absorbance at 405 nm was measured. As shown in Fig. 3, the binding of the chimeric protein was observed in a botrocetin and von Willebrand factor amount dependent manner.

(2) Detection of chimeric protein binding using europium (Eu) labeling method

[0110] The chimeric protein (GPIb-mIgG2aFc) solution purified by the Protein A column, which was obtained in Example 3, was dialyzed against physiological saline. The solution of about 200 μ g/1.5 ml was concentrated to 780 μ l (concentration of about 250 μ g/ml) by ultrafiltration using Centricon-10 (produced by Amicon). 500 μ l of the concentrated solution (containing about 125 μ g of GPIb-mIgG2aFc) was added with 50 μ l of 0.5 M NaHCO₃, then added with 50 μ l of a solution obtained by dissolving 0.2 mg of Eu-Labeling Reagent (europium DTTA-isothiocyanate as compound, DELFIA 1244-302, produced by Wallac) in 250 μ l of physiological saline, and stirred at room temperature for about 40 hours to allow the reaction of europium DTTA-isothiocyanate.

[0111] The above reaction mixture was subjected to gel filtration using HiLoad16/60 Superdex 75pg (inner diameter of 16 mm, length of 60 cm, produced by Pharmacia) to separate the unreacted reagent and the chimeric protein. The gel filtration was performed at a flow rate of 1 ml/minute by using physiological saline as the eluant. The chimeric protein labeled with Eu was recovered in fractions of the elution volume of 40 to 48 ml. The protein was quantified by using a protein assay kit (Protein Assay, produced by Bio-Rad) and IgG as a standard substance. As a result, the concentration of the labeled chimeric protein in the eluted solution had a concentration of 6.4 μ g/ml. Hereafter, the following experiments were conducted by using this value as the chimeric protein concentration.

[0112] The binding of the europium (Eu) labeled chimeric protein and the von Willebrand factor immobilized in the presence of botrocetin prepared as described above was detected as follows. According to the method mentioned in Example 4 (1), a mixed solution (TBS) containing 2.5 μ g/ml of von Willebrand factor and 2.5 μ g/ml of botrocetin was added to each well of a 96-well multiliter plate (microtitration plate DELFIA, 1244-550, produced by Wallac), immobilized overnight and subjected to washing, blocking and washing to prepare a von Willebrand factor immobilized plate.

[0113] Each well of the above plate was added with 25 μ l of an assay buffer containing 0.5% BSA (Assay Buffer, Wallac DELFIA 1244-106, produced by Wallac, Composition: 0.5% BSA, 0.05% bovine γ -globulin, 0.01% Tween-40, 20 μ M DTPA (diethylenetriamine tetraacetic acid), 50 mM Tris-HCl buffered saline (pH 7.8), 0.05% sodium azide) or the recombinant AS1051 (in which Cys81 was replaced with Ala, N. Fukuchiet al., WO 95/08573) at a final concentration of 20 μ g/ml as the binding inhibition substance, further added with 25 μ l of a solution of europium (Eu) labeled chimeric protein in the same assay buffer (100 ng/ml), shaken for 1 minute for stirring, and then left stand at room temperature for 2 hours. Each well of the plate was washed 5 times with TBS (150 μ l) containing 0.05% Tween-20, then added with 100 μ l of a fluorescence enhancement buffer (Enhancement buffer, 1244-104, produced by Wallac, Composition: 15 μ M β -NTA (2-naphthoyl trifluoroacetone), 50 μ M TOPO (tri-n-octylphosphine oxide), 1 g/L Triton X-100, 100 mM acetic acid/potassium hydrogen phthalate buffer), and shaken for 1 minute for stirring. Then, the amount of europium (Eu) was measured by using a DELFIA Research fluorophotometer (1230 ARCUS Fluorometer, produced by Wallac, measurement time: 1 second). The measured values (with addition or no addition of the binding inhibition substance) and CV value (deviation, %) are shown in Table 1.

Table 1

Measured value and CV value (%) by Eu-labeling method	
Average value of count in control (n=80)	26668 cpm
CV value (%)	6.75%
Average value of count with addition of AS1051 (10 μ g/ml)(n=6)	935 cpm
S/N ratio	28.5

Example 5: Detection of inhibition by binding inhibition substance for binding of von Willebrand factor and chimeric protein

(1) Detection of inhibition for binding of chimeric protein by ELISA using anti-mouse IgG-Fc antibodies

[0114] The detection was carried out in the same manner as that of Example 4 (1) except that von Willebrand factor was immobilized by using a mixed solution (TBS) containing 2.5 µg/ml of von Willebrand factor and 2.5 µg/ml of botrocetin, and a binding inhibition substance of which inhibitory activity was desired to be measured was added to the reaction of the immobilized von Willebrand factor and the culture supernatant of the chimeric protein producing cells.

[0115] As the binding inhibition substance, AJvW-2, which is an anti-human von Willebrand factor monoclonal antibody, and a human glycoprotein Ib binding peptide derived from snake venom of *Crotalus horridus horridus* were used.

[0116] The hybridoma producing AJvW-2 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code: 305, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) on August 24, 1994, and given an accession number of FERM P-14487. Then, it was transferred to an international deposit under the provisions of the Budapest Treaty on September 29, 1995, and given an accession number of FERM BP-5248 (refer to WO96/17078). AJvW-2 can be obtained by culturing this hybridoma.

[0117] The aforementioned human glycoprotein Ib binding peptide corresponded to a single chain peptide obtained from a multi-mer peptide derived from snake venom of *Crotalus horridus horridus* (AS1051) in which 81-cysteine residue was replaced with an alanine residue (variant type AS1051). The variant type AS1051 was obtained by modifying the gene coding for AS1051 so that the 81-cysteine residue should be replaced with an alanine residue, and expressing it in *Escherichia coli*. *E. coli* HB101/pCHA1 (*E. coli* AJ13023) harboring pCHA1 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code: 305, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) on August 12, 1994 as an international deposit under the provisions of the Budapest Treaty, and given an accession number of FERM BP-4781 (refer to WO95/08573). AS1051 itself is also a human glycoprotein Ib binding peptide, and it can be detected in the same manner as that for the variant type AS1051.

[0118] The inhibitory activities of AJvW-2 and the variant type AS1051 for the binding of the chimeric protein (i.e., glycoprotein Ib) are shown in Fig. 4.

(2) Detection of inhibition for binding of chimeric protein by europium (Eu) labeling method

[0119] The detection was carried out in the same manner as that of Example 4 (2) except that von Willebrand factor was immobilized by using a mixed solution (TBS) containing 2.5 µg/ml of von Willebrand factor and 2.5 µg/ml of botrocetin, and a binding inhibition substance of which inhibitory activity was desired to be measured was added to the reaction of the immobilized von Willebrand factor and the chimeric protein labeled with europium (Eu).

[0120] As the binding inhibition substance, AJvW-2, which is an anti-human von Willebrand factor monoclonal antibody, and the variant type AS1051. The inhibitory activities of the both substances for the binding of the chimeric protein (i.e., glycoprotein Ib) are shown in Fig. 5.

Example 6: Detection of glycocalicin in plasma

(1) Detection of glycocalicin by ELISA using anti-mouse IgG-Fc antibodies

[0121] Human plasma was prepared by collecting blood from healthy volunteers using an injection needle of 18G, adding 1/10 volume of 3.8% aqueous sodium citrate solution to the blood, and centrifuging the mixture at 3000 x rpm for 10 minutes to separate a supernatant.

[0122] Each human plasma collected independently from three volunteers was successively diluted 2-fold (8 times of dilution in total), and 25 µl of the plasma was added to each well of the plate. Each well of the plate was further added with 25 µl of a solution prepared by diluting 8-fold a culture supernatant obtained from culture of the chimeric protein producing cells in a serum-free medium with TBS containing 0.1% BSA, and incubated at room temperature for 1 hour. The subsequent reactions and color development were performed in the same manner as Example 5(1), and the average values of the results are shown in Fig. 6.

[0123] The blood concentration of glycocalicin in healthy people was reported to be about 2 µg/ml. On the other hand, the glycocalicin concentration showing 50% binding inhibition in this detection system was about 400 ng/ml. From this fact, it was considered that a glycocalicin amount of 60 ng/ml or more could sufficiently be measured in view of the linearity of the plot.

(2) Detection of glycocalcin using chimeric protein labeled with europium (Eu)

[0124] Each human plasma independently prepared in the same manner as the above (1) were successively diluted 2-fold with TBS (8 times of dilution in total), and 25 μ l each of the diluted plasma was added to each well of a von Willebrand factor immobilized plate prepared in the same manner as in Example 5 (1) (microtitration plate DELFIA, 1244-550, produced by Pharmacia Biotech, was used as the base plate). Further, 25 μ l a solution of the chimeric protein labeled with europium (Eu) in assay buffer prepared in the same manner as in Example 4 (1) (100 ng/ml, Assay Buffer; 1244-106, produced by Pharmacia Biotech) was added to each well of the plate for reaction. The subsequent washing and measurement were performed in the same manner as in Example 5 (2), and the average values of the results are shown in Fig. 7.

[0125] The blood concentration of glycocalcin in healthy people was reported to be about 2 μ g/ml. On the other hand, the glycocalcin concentration showing 50% binding inhibition was about 60 ng/ml in this detection system. From this fact, it was considered that a glycocalcin amount of 30 ng/ml or more could sufficiently be measured.

15 Example 7: Detection of binding of chimeric protein to immobilized von Willebrand factor in the presence of botrocetin and detection of binding inhibition by binding inhibition substance

(1) Detection of binding of chimeric protein

[0126] A TBS solution (50 μ l) containing human von Willebrand factor (2.5 μ g/ml) was added to each well of a 96-well plate, and the von Willebrand factor was immobilized as a solid phase overnight at 4°C. Each well was washed once with TBS (150 μ l) and blocked with TBS containing 5% BSA for about 3 hours. Each well of the plate was washed twice with TBS (150 μ l), and then added with 25 μ l of an assay buffer (Assay Buffer, Wallac DELFIA 1244-106, produced by Wallac, composition was mentioned in Example 4 (2) or a recombinant AS1051 (in which Cys81 was replaced with Ala) at a final concentration of 20 μ g/ml, further added with the assay buffer (25 μ l) containing the europium (Eu)-labeled chimeric protein prepared in Example 4 (2) (100 ng/ml) and botrocetin (500 ng/ml), and left stand at room temperature for 3 hours. Each well of the plate was washed 5 times with TBS (150 μ l) containing 0.05% Tween-20, then added with 100 μ l of a fluorescence enhancement buffer (Enhancement solution, 1244-104, produced by Wallac, composition was mentioned in Example 4 (2)), and shaken for 1 minute. Then, the amount of europium (Eu) was measured by using a 1420 ARVO multi-label counter (produced by Wallac, measurement time: 1 second). The measured values (with no addition of sample or addition of the inhibition sample) and CV value (deviation, %) are shown in Table 2.

Table 2

Measured value and CV value (%) obtained by method utilizing presence of botrocetin in liquid phase	
Average value of count in control (n=80)	70220 counts
CV value (%)	8.2%
Average value of count with addition of AJvW-2 (10 μ g/ml) (n=16)	2014 counts
S/N ratio	35

45 (2) Measurement of inhibition for binding of chimeric protein by inhibition substance

[0127] The measurement was performed in the same manner as in Example 7 (1) except that a binding inhibition substance of which inhibition activity was desired to be measured was added.

[0128] As the inhibition substance, AJvW-2 mentioned in Example 5 (1), which is an anti-human von Willebrand factor monoclonal antibody, and the variant type AS1051 similarly mentioned in Example 5 (1), which is a human glycoprotein Ib binding protein, were used.

[0129] The inhibitory activities for the binding of the chimeric protein (i.e., glycoprotein Ib) of AJvW-2 and the variant type AS1051 are shown in Fig. 8.

Example 8: Detection of binding of von Willebrand factor to immobilized chimeric protein in the presence of binding inducing substance and detection of binding inhibition by binding inhibition substance

(1) Detection of binding using botrocetin

[0130] First, 500 μ l of a solution of human von Willebrand factor in physiological saline (300 μ g/ml) was added with 50 μ l of 0.5 M NaHCO₃, then added with 50 μ l of a solution formed by dissolving 0.2 mg of Eu-labeling Reagent (Europium DTTA-isothiocyanate as compound, DELFIA 1244-302, produced by Wallac) in 250 μ l of physiological saline, and allowed to react at room temperature for about 40 hours with stirring.

[0131] The above reaction mixture was subjected to gel filtration using HiLoad 16/60 Superdex 75pg (inner diameter of 16 mm, length of 60 cm, produced by Pharmacia) to separate unreacted reagents and von Willebrand factor. The gel filtration was performed at a flow rate of 1 ml/minute by using physiological saline as eluate. The human von Willebrand factor labeled with Eu was collected in fractions of 40 to 48 ml of elution volume.

[0132] The binding of von Willebrand factor labeled with europium (Eu), which was prepared as described above, and the immobilized chimeric protein in the presence of botrocetin was detected as follows. First, 50 μ l of a solution of anti-mouse immunoglobulin polyclonal antibodies (Catalog No. 55482, produced by Organon Teknika, 1 μ g/ml) in 0.1 M sodium carbonate buffer (pH 9.6) was added to each well of a 96-well multititer plate (microtitration plate DELFIA, 1244-550, produced by Wallac), and the antibodies were immobilized overnight. Then, each well was washed, blocked with TBS (100 μ l) containing 5% BSA, and washed 3 times with TBS (150 μ g/ml). Further, 50 μ l of a solution of the chimeric protein (0.5 μ g/ml) in TBS was added to each well and left stand at room temperature for 3 hours to allow the chimeric protein to bind to the immobilized anti-mouse immunoglobulin antibodies. Thus, a chimeric protein immobilized plate was prepared.

[0133] Each well of the chimeric protein immobilized plate was washed 3 times with TBS (150 μ l) containing 0.05% Tween-20. Then, in the same manner as mentioned in Example 4 (1), each well of the plate was added with 25 μ l of an assay buffer (Assay Buffer, 1244-106, produced by Wallac, composition was mentioned in Example 4 (2)) or a recombinant AS1051 (in which Cys81 was replaced with Ala) as the inhibition substance at a final concentration of 20 μ g/ml, further added with the assay buffer (25 μ l) containing the europium (Eu)-labeled von Willebrand factor (500 ng/ml) and botrocetin (500 ng/ml), and left stand at room temperature for 3 hours. Each well of the plate was washed 5 times with TBS (150 μ l) containing 0.05% Tween-20, then added with 100 μ l of a fluorescence enhancement buffer (Enhancement solution, 1244-104, produced by Wallac, composition was mentioned in Example 4 (2)), and shaken for 1 minute. Then, the amount of europium (Eu) was measured by using a 1420 ARVO multi-label counter (produced by Wallac, measurement time: 1 second). The measured values (with no addition of sample or addition of the inhibition sample) are shown in Table 3.

Table 3

Measured value obtained by method utilizing immobilization of chimeric protein (in the presence of botrocetin)	
Average value of count in control	37267 counts
Average value of count with addition of AJvW-2 (10 μ g/ml)	2339 counts

(2) Measurement of inhibition for binding of chimeric protein by inhibition substance

[0134] The measurement was performed in the same manner as in Example 8 (1) except that a binding inhibition substance of which inhibition activity was desired to be measured was added.

[0135] As the inhibition substance, AJvW-2 mentioned in Example 5 (1), which is an anti-human von Willebrand factor monoclonal antibody, and the variant type AS1051 similarly mentioned in Example 5 (1), which is a human glycoprotein Ib binding protein, were used.

[0136] The inhibitory activities of AJvW-2 and the variant type AS1051 for the binding of the chimeric protein (i.e., glycoprotein Ib) are shown in Fig. 9.

(3) Detection of binding using ristocetin

[0137] Von Willebrand factor labeled with europium (Eu) and a chimeric protein immobilized plate that were prepared in the same manner as the above (1) were used. Each well of the chimeric protein immobilized plate was washed 3 times with TBS (150 μ l) containing 0.05% Tween-20. Then, each well of the above plate was added with 25 μ l of the

assay buffer (Assay Buffer, 1244-106, produced by Wallac, composition was mentioned in Example 4 (2) or the recombinant AS1051 (in which Cys81 was replaced with Ala) at a final concentration of 20 µg/ml, further added with an assay buffer (25 µl) containing von Willebrand factor (500 ng/ml) and ristocetin sulfate (produced by Sigma) at one of various concentrations (2, 1, 0.5, 0.25 and 0 mg/ml), and left stand at room temperature for 2 hours. Each well of the plate was washed 5 times with TBS (150 µl) containing 0.05% Tween-20, added with 100 µl of a fluorescence enhancement buffer (Enhancement solution, 1244-104, produced by Wallac, composition was mentioned in Example 4 (2)), and shaken for 1 minute. Then, the amount of europium (Eu) was measured by using a 1420 ARVO multi-label counter (produced by Wallac, measurement time: 1 second). The concentration of ristocetin, count of bound von Willebrand factor, and count of von Willebrand factor bound in the presence of the recombinant AS1051 (final concentration: 20 µg/ml) are shown in Table 4.

Table 4

Binding amount of von Willebrand factor at various ristocetin concentrations (measured values)		
Ristocetin concentration	Binding amount (count)	Binding amount in the presence of inhibition substance (count)
2 mg/ml	46213 counts	6884 counts
1 mg/ml	13327 counts	3015 counts
0.5 mg/ml	3665 counts	1852 counts
0.25 mg/ml	3008 counts	3083 counts
0 mg/ml	2818 counts	3246 counts

Example 9: Screening of substance that inhibits binding of glycoprotein Ib and von Willebrand factor using method of Example 7

[0138] A substance that inhibits the binding of glycoprotein Ib and von Willebrand factor was screened by using the method of Example 7. Specifically, it was performed in the same manner as in Example 7 (1) except that a sample of which inhibitory activity was desired to be measured was added. Various compounds, culture broth of actinomycetes, filamentous fungi and so forth or organic solvent extracts thereof were used as samples.

[0139] As a result, a substance that markedly inhibited the binding of glycoprotein Ib and von Willebrand factor was found in culture broth of AJ9553 strain of actinomycete collected from soil of Shiki no Mori Koen in Yokohama-shi, Kanagawa-ken, Japan or its organic solvent (butanol and ethyl acetate) extraction fraction.

Example 10: Production, isolation and structural analysis of inhibition substance using actinomycete AJ9553 strain

(1) Method for producing K17427A and K17427B from AJ9553 strain

[0140] The AJ9553 strain was inoculated to 5 ml of a seed culture medium (containing 0.1% beef extract (produced by DIFCO), 1% glucose, 1% starch soluble (produce by Nakarai Tesque), 0.5% corn steep powder (produced by Wako Pure Chemicals), 1% polypeptone (produced by Dainippon Pharmaceutical), 0.5% yeast extract (produced by DIFCO) and 0.2% calcium carbonate, pH 7.2) contained in a test tube, and cultured at 28°C for 6 days with shaking at 120 rpm. This culture broth was inoculated at a concentration of 2% to 70 ml of culture medium (containing 2% glycerol, Pharammedia (produced by Traders Protein), 1% corn steep powder (produced by Nakarai Tesque), 0.4% calcium carbonates, 0.3% sodium sulfate and 0.003% of zinc sulfate heptahydrate, pH 7.0) contained in a 500-ml volume Erlenmeyer flask, and further cultured at 28°C for 8 days with shaking at 180 rpm.

[0141] From the culture broth (1.6 L) obtained as described above, cells were collected by centrifugation, and acetone (1 L x 2) was added to the cells to extract them at room temperature for 1 day. The cell debris was separated by filtration, and then the acetone was evaporated under reduced pressure. The obtained residue was suspended in water. This aqueous suspension was adjusted to pH 2.0 with 5% hydrochloric acid, and added with ethyl acetate (400 ml x 2) to extract it. The ethyl acetate layer was concentrated under reduced pressure, and the obtained residue (1.3 g) was dissolved in 50% methanol. This solution was eluted with methanol using a column filled with DIA ION HP-20 (Mitsubishi Chemical). The obtained fraction was purified by HPLC using an ODS column (YMC-Pack AM-322) to obtain

K17427A (400 mg) and K17427B (40 mg).

(2) Method for producing K17427C and K17427D from AJ9553 strain

5 [0142] The AJ9553 strain was inoculated to 5 ml of a seed culture medium (containing 0.1% beef extract (produced by DIFCO), 1% glucose, 1% starch soluble (produce by Nakarai Tesque), 0.5% corn steep powder (produced by Wako Pure Chemicals), 1% polypeptone (produced by Dainippon Pharmaceutical), 0.5% yeast extract (produced by DIFCO) and 0.2% calcium carbonate, pH 7.2) contained in a test tube, and cultured at 28°C for 6 days with shaking at 120 rpm.

10 [0143] From the culture broth (40 ml) obtained as described above, cells were collected by centrifugation, and acetone (1 L x 2) was added to the cells to extract them at room temperature for 1 day. The cell debris was separated by filtration, and then the acetone was evaporated under reduced pressure. The obtained aqueous suspension was adjusted to pH 2.0 with 5% hydrochloric acid, and added with ethyl acetate (20 ml x 2) to extract it. The ethyl acetate layer was concentrated under reduced pressure, and the obtained residue was dissolved in 50% methanol. This solution was eluted with methanol using a column filled with DIA ION HP-20 (Mitsubishi Chemical). The obtained fraction was fractionated by preparative silica gel TLC (Merck, n-hexane/ethyl acetate/methanol/water = 60:40:5:0.5) to obtain K17427C (3.2 mg) and K17427D (2.2 mg).

Example 11: Identification and physiological test of actinomycete AJ9553 strain producing low molecular weight substance K17427A, B, C and D, which inhibit binding of glycoprotein Ib and von Willebrand factor

20 [0144] The results of taxonomic examination of the AJ9553 strain producing K17427A, B, C and D are shown below.

1. Morphological characteristics

25 [0145] After culture on the agar medium defined by ISP (International Streptomyces Project) at 28°C for 14 days, it was found by microscopic observation that substrate mycelia fairly elongated and branched, and exhibited orange color. The zigzag elongation like *Nocardia* strains was not observed. Aerial mycelia were formed from substrate mycelia, and spore chains were formed after maturation. Sporangia were not formed. Spores were arthospores in an egg-like shape or single rod-like shape, and they usually had a size of 0.4 to 1 x 1 to 1.5 µm. When matured spores were put into water, the spores had flagella and showed migration property.

2. Growth on various agar media and appearance of cultured actinomycete

35 [0146] Growth on various agar media and appearance of the cultured actinomycete (cultured at 28°C for 14 days) are shown in Table 5.

Table 5

Growth on various agar media and appearance of the cultured actinomycete (cultured at 28°C for 14 days)				
Medium	Growth	Color of substrate mycelium	Sporangium	Soluble pigment
Yeast-malt agar medium (ISP-2)	Good	Orange	Not formed	Yellow
Oatmeal agar medium (ISP-3)	Good	Dark yellow	Not formed	Yellow
Starch-mineral salt agar medium (ISP-4)	Good	Yellow	Slightly formed	Yellow
Glycerin-asparagine agar medium (ISP-5)	Good	Pale orange	Not formed	Not observed
Tyrosine agar medium (ISP-7)	Good	Reddish brown	Abundantly formed	Dark brown (melanin-like)
Nutrient agar medium	Normal	Reddish orange	Not formed	Yellow
Aqueous agar	Poor	Pale yellow	Abundantly formed	Not observed

3. Growth Temperature

5 [0147] Growth states after culture on the oatmeal agar medium for 14 days are represented below.

8°C: No growth	30°C: Good growth
18°C: Slight growth	37°C: Good growth
20°C: Normal growth	42°C: Normal growth
28°C: Good growth	45°C: No growth.

10 15 20 25 30 4. Utilization of carbon source

[0148] The strain was cultured at 28°C for 14 days on Pridham-Gottlieb's agar as a basal medium supplemented with each of the following various saccharides. The growth conditions are shown below. "-" indicates no growth, and "+" indicates normal growth.

D-Glucose	+	Raffinose	-
D-Xylose	+	D-Mannitol	+
L-Arabinose	+	Inositol	-
L-Rhamnose	+	Sucrose	+
D-Fructose	+	D-Galactose	+

5. Cell components

[0149] There were found meso-diaminopimelate, 3-OH-diaminopimelate, glycine and lysine in the cell wall, and the cell fluid type was considered to be VI type. The total cell saccharide components, which constitute a taxonomic characteristic, were arabinose and xylose, and hence the saccharide pattern was D type. The major menaquinone was MK-9 (H4). Further, the acyl type of the cell wall peptidoglycan was glycolyl type.

35 40 45 50 55 6. Nucleotide sequence analysis of 16S ribosome RNA

[0150] Nucleotide sequence analysis of 16S ribosome RNA of this strain revealed that this strain was most close to *Couchioplanes caeruleus* belonging to the family *Micromonosporaceae*.

[0151] Based on the above, it was clear that the strain belonged to the genus *Couchioplanes* among actinomycetes, and thus the AJ9553 strain was decided to be referred to as *Couchioplanes* sp. AJ9553.

[0152] This strain was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code: 305-8566, 1-3, Higashi 1-chom, Tsukuba-shi, Ibaraki-ken, Japan) on January 6, 1999 under the provisions of the Budapest Treaty, and given an accession number of FERM BP-6612.

[0153] In the present invention, derivatives of *Couchioplanes* sp. AJ9553 such as variant strains thereof can also be used for the production of the inhibition substance so long as they have a property for producing an inhibition substance, even though they have physiological characteristics different from those of the strain. A variant strain can be obtained by mutating *Couchioplanes* sp. AJ9553 by means of a usual method for mutagenizing a bacterial strain, for example, irradiation treatment such as irradiation with X-rays or ultraviolet rays, treatment with a mutagenizing agent such as nitrogen mustard, azaserine, nitrous acid, 2-aminopurine and N-methyl-N'-nitrosoguanidine (NTG), contact with phage, transformation, transfection, conjugation and so forth.

Example 12: Inhibitory activity of K17427A, C and D for binding of glycoprotein Ib and von Willebrand factor

(1) Measurement of inhibitory activity of K17427A, C and D using method of Example 4 for detecting inhibition for binding of glycoprotein Ib and von Willebrand factor

[0154] The inhibitory activity of the isolated K17427A, C and D for the binding of glycoprotein Ib and von Willebrand factor was measured in the same manner as Example 4, except that a 1420 ARVO multi-label counter (produced by Wallac, measurement time: 1 second) was used for the measurement. The inhibitory activity of each compound for the binding of glycoprotein Ib and von Willebrand factor was shown in Fig. 10.

(2) Measurement of inhibitory activity of K17427A, C and D for binding of ^{125}I -labeled von Willebrand factor and formalin-fixed platelets

(1) Preparation of fixed platelets

[0155] Fixed platelets were prepared as follows. 50 ml of blood collected from healthy volunteers using an injection needle of 18G was added with 1/10 volume of 3.8% sodium citrate, divided into two 50-ml disposable tubes (Falcon 2096) in equal volumes, and centrifuged at 900 rpm for 15 minutes at room temperature by using a refrigerated centrifuge (KUBOTA 8800) to collect the supernatant as platelet rich plasma (PRP). PRP was added with an equal volume of 2% paraformaldehyde/PBS, gently stirred and left stand overnight at 4°C. The solution was centrifuged at 3000 rpm for 10 minutes using the same refrigerated centrifuge as above, and the supernatant was removed by decantation. The precipitates were added with about 20 ml of PBS and suspended with gentle pipetting. After the centrifugation at 3000 rpm for 10 minutes and suspension with PBS were further repeated twice, and then a PBS solution of the same volume as the original PRP amount was finally obtained and used as fixed platelet suspension.

(2) Purification of von Willebrand factor from human serum

[0156] Von Willebrand factor was purified from human serum according to the method to H.R. Gralnick *et al.* (*J. Clin. Invest.*, 62, 496 (1978)).

(3) Labeling of von Willebrand factor with ^{125}I

[0157] In a tube in which labeling with ^{125}I was to be performed, lodogen (produced by Pearce) was immobilized as a solid phase beforehand by adding 1.5 ml of a solution of lodogen (0.5 mg/ml) in dichloromethane to the tube and removing the solvent under argon flow. High molecular weight von Willebrand factor (0.19 mg/1.5 ml) obtained by gel filtration was introduced into the reaction tube, added with 18.5 Mbq of Na^{125}I , and allowed to react at room temperature for 2 minutes. The reaction mixture was applied to a PD10 (produced by Pharmacia Biotech) column blocked with BSA and washed beforehand, and eluted with TBS. The eluate was collected as 0.5-ml fractions, and ^{125}I specific activity of each fraction was measured by using a gamma counter, Packard Multi Pries 4. The fractions containing ^{125}I -von Willebrand factor in a large amount were combined, then divided into several tubes and stored at -80°C until use.

(4) Measurement of inhibitory activity of K17427A, C and D for binding of ^{125}I -von Willebrand factor to immobilized platelets

[0158] A 96-well filter plate, Millipore Multiscreen HV (produced by Millipore, 0.45 μM), on which the assay was to be performed, was preliminarily blocked by adding 1% BSA/TBS (100 μl) to each well of the filter and leaving it stand for several hours. Then, 20 μl of a suspension obtained by diluting the aforementioned immobilized platelet suspension 10-fold with TBS and 5 μl of a test sample were added to each well, and 25 μl (about 800,000 cpm) of ^{125}I -von Willebrand factor solution containing 0.8 $\mu\text{g}/\text{ml}$ of botrocetin or 2.4 mg/ml of ristocetin was further added to each well. The filter plate was left stand for 30 minutes. The solution in the wells was filtered by suction, and each well was washed by adding TBS (100 μl) containing 0.05% Tween-20 and sucking it.

[0159] The measurement using the gamma counter was performed as follows. Filter pieces were cut from the 96-well filter plate after the above washing by using a punch (produced by Millipore, Model number: MAPK 896 OB), put into 6-ml volume polystyrene tubes respectively, and measured for radiation dose of ^{125}I by using Packard Multi Pries 4. The inhibitory activities of K17427A, C and D are shown in Fig. 11.

[0160] As shown in the aforementioned results of (1) and (2), the inhibitory activities of K17427A, C and D enabled the detection with higher sensitivity by the method of (1) (the method of Example 4) according to the present invention, compared with the usually and widely used method described in (2).

Example 13: Inhibitory activity of K17427A for platelet aggregation

5 [0161] 50 ml of blood collected from healthy volunteers using an injection needle of 18G was added with 1/10 volume of 3.8% sodium citrate, divided into two 50-ml disposable tubes (Falcon 2096) in equal volumes, and centrifuged at 900 rpm for 15 minutes at room temperature by using a refrigerated centrifuge (produced by TOMY) to collect the supernatant as platelet rich plasma (PRP). The lower layer was further centrifuged at 1500 rpm for 10 minutes at room temperature, and the supernatant was collected as platelet poor plasma (PPP). The platelet aggregation inhibitory activity of a test sample was measured by using PRP prepared as described above and Hematracer 801 (produced by Niko Bioscience) as a measurement apparatus. A special cuvette for the measurement preliminarily containing a test sample (2.5 to 5 μ l) was added with 100 μ l of PRP and mounted on the measurement apparatus. The sample was stirred for 2 minutes (37°C), added with a aggregation substance solution of 10-fold concentration, and measured for change of light transmission. The light transmitting PRP was taken as 0%, and the light transmitting PPP as 100%. The aggregation inhibition ratio obtained by the inhibition substance was numerically represented according to the following equation.

15

$$\text{Aggregation inhibition ratio} = \\ 100 - (\text{Aggregation ratio with addition of inhibition substance} - \text{Aggregation ratio immediately after} \\ \text{addition of aggregation substance}) / (\text{Control aggregation ratio} - \text{Aggregation ratio immediately} \\ \text{after addition of aggregation substance}) \times 100$$

20

25 [0162] As the aggregation inducing substance, ristocetin sulfate (produced by Sigma, final concentration: 1.2 mg/ml), adenosine diphosphate (ADP, produced by MC Medical, final concentration: 10 μ M) and collagen (produced by MC Medical, final concentration: 10 μ g/ml) were used.

30 [0163] The inhibitory activities of K17427A for the aggregation induced by each aggregation inducing substance are shown in Fig. 12. The aggregation inhibition ratios at various concentrations for platelet aggregation caused by each aggregation inducing substance, which were calculated as described above, are shown in Table 4.

35

Table 4

Aggregation inhibition ratios at various concentrations of K17427A for platelet aggregation caused by each aggregation inducing substance			
	Ristocetin aggregation	ADP aggregation	Collagen aggregation
1 mM	100%	24%	1%
0.5 mM	84%	8%	0%
0.25 mM	0%	7%	-7%

40

45 [0164] Although K17427A completely inhibited the aggregation induced by ristocetin at a concentration of 500 μ M or higher, it did not substantially inhibit the aggregation induced by ADP or collagen even at 1 mM. While the inhibition activities of K17427B, C and D were not measured, it can readily be estimated that they similarly specifically inhibit only the aggregation induced by ristocetin, from the facts that they have highly analogous structures and they inhibit the binding of glycoprotein Ib and von Willebrand factor as shown in Example 12.

Industrial Applicability

50 [0165] According to the present invention, the binding of glycoprotein Ib and von Willebrand factor or inhibition thereof can be detected in a simple manner. According to the method of the present invention, there are provided a simple method for quantification of glycocalicin with superior quantification ability, and a simple method for measurement of a substance inhibiting the binding of von Willebrand factor and glycoprotein Ib with superior operability.

55 [0166] If von Willebrand factor is immobilized in the presence of a binding inducing substance such as botrocetin, the binding of von Willebrand factor and glycoprotein Ib can be observed in a simple manner with good reproducibility, without adding a binding inducing substance such as botrocetin or ristocetin to a liquid phase.

[0167] Further, by utilizing the chimeric protein of the present invention, it becomes unnecessary to prepare or obtain monoclonal antibodies for detection or quantification of a binding inhibition substance such as glycocalicin.

[0168] Moreover, the present invention also provides a method for preparing a chimeric molecule (chimeric protein)

that comprises a partial protein of glycoprotein Ib bound to the Fc region of immunoglobulin molecule by using animal cells.

5 **Claims**

1. A method for detecting binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding, comprising the steps of:

10 immobilizing von Willebrand factor in a reaction vessel in the presence of a substance inducing the binding of von Willebrand factor and glycoprotein Ib, and,
reacting the immobilized von Willebrand factor with glycoprotein Ib.

15 2. The method according to Claim 1, wherein the substance that induces the binding of von Willebrand factor and glycoprotein Ib is botrocetin, ristocetin or the both substances.

20 3. The method according to Claim 1, wherein glycocalicin is measured by adding a sample containing glycocalicin to the reaction vessel during the reaction of von Willebrand factor and glycoprotein Ib, or prior to the reaction, and detecting inhibition of the binding of von Willebrand factor and glycoprotein Ib.

25 4. The method according to Claim 1, wherein a substance that inhibits the binding of von Willebrand factor and glycoprotein Ib is detected by adding a sample containing a substance to be detected to the reaction vessel during the reaction of von Willebrand factor and glycoprotein Ib, or prior to the reaction, and detecting inhibition of the binding of von Willebrand factor and glycoprotein Ib.

5. A method for detecting binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding, comprising the steps of:

30 binding a chimeric protein that consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Ib α chain at its carboxyl terminus or the chimeric protein labeled with a labeling substance to von Willebrand factor immobilized in a reaction vessel, and
detecting the Fc region of the immunoglobulin molecule or the labeling substance.

35 6. The method according to Claim 5, wherein, when the chimeric protein is allowed to bind to von Willebrand factor, or prior to the binding, a substance that induces the binding of von Willebrand factor and glycoprotein Ib is added to the reaction vessel.

40 7. The method according to Claim 6, wherein the substance that induces the binding of von Willebrand factor and glycoprotein Ib is botrocetin, ristocetin or the both substances.

8. The method according to Claim 6, wherein von Willebrand factor is immobilized in the reaction vessel in the presence of a substance that induces the binding of von Willebrand factor and glycoprotein Ib.

45 9. The method according to Claim 5, wherein glycocalicin is measured by adding a sample containing glycocalicin to the reaction vessel when the chimeric protein is allowed to bind to von Willebrand factor, or prior to the binding, and detecting inhibition of the binding of von Willebrand factor and the chimeric protein.

50 10. The method according to Claim 5, wherein a substance that inhibits the binding of von Willebrand factor and glycoprotein Ib is detected by adding a sample containing a substance to be detected to the reaction vessel when the chimeric protein is allowed to bind to von Willebrand factor, or prior to the binding, and detecting inhibition of the binding of von Willebrand factor and the chimeric protein.

55 11. A method for detecting binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding, comprising the steps of:

immobilizing a chimeric protein that consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Ib α chain at its carboxyl terminus in a reaction vessel,

binding von Willebrand factor or labeled von Willebrand factor to the chimeric protein, and detecting bound von Willebrand factor or the labeling substance.

12. The method according to Claim 11, wherein, when the chimeric protein is allowed to bind to von Willebrand factor, or prior to the binding, a substance that induces the binding of von Willebrand factor and glycoprotein Ib is added to the reaction vessel.
13. The method according to Claim 12, wherein the substance that induces the binding of von Willebrand factor and glycoprotein Ib is botrocetin, ristocetin or the both substances.
14. The method according to Claim 12, wherein glycocalicin is measured by adding a sample containing glycocalicin to the reaction vessel when von Willebrand factor is allowed to bind to the chimeric protein, or prior to the binding, and detecting inhibition of the binding of von Willebrand factor and the chimeric protein.
15. The method according to Claim 12, wherein a substance that inhibits the binding of von Willebrand factor and glycoprotein Ib is detected by adding a sample containing a substance to be detected to the reaction vessel when von Willebrand factor is allowed to bind to the chimeric protein, or prior to the binding, and detecting inhibition of the binding of von Willebrand factor and glycoprotein Ib.
16. A chimeric protein, which consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Ib α chain at its carboxyl terminus.
17. The chimeric protein according to Claim 16, wherein the immunoglobulin molecule is derived from mouse.
18. A kit for measuring glycocalicin based on inhibition of a reaction of von Willebrand factor and glycoprotein Ib, comprising von Willebrand factor and a chimeric protein that consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Ib α chain at its carboxyl terminus.
19. A compound which is detected by the method according to any one of Claims 1, 5 and 12, which has an activity for specifically inhibiting platelet aggregation involving glycoprotein Ib and von Willebrand factor in blood plasma and a molecular weight of not more than 2000.
20. The compound according to Claim 19, which has a structure represented by the following formula:


35

40

45

50

55



wherein R¹ and R² independently represent H or Cl, and R³ represents CH₃ or H.

30

35

40

45

50

55




Fig. 1




Fig. 2

Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8

binding[%]




Fig. 9

binding[%]




Fig. 10




Fig. 11







Fig. 12



INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP99/00089

A. CLASSIFICATION OF SUBJECT MATTER
Int.Cl⁶ C07K19/00, 14/47, 16/00, G01N33/566, 33/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
Int.Cl⁶ C07K19/00, 14/47, 16/00, G01N33/566, 33/53

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CA (STN), REGISTRY (STN), BIOSIS (DIALOG)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YOKO, MINAMOTO et al., "Detection of platelet adhesion/aggregation to immobilized ligands on microbeads by an aggregometer", Thromb. Haemostasis, Vol. 76(6)(1996), p.1072-1079, Refer to ABSTRACT, RESULTS, DISCUSSION	1-4
A	S. MIURA et al., "Inhibition assay for the binding of biotinylated von willebrand factor to platelet-bound microtiter wells in the presence of ristocetin or bortrocetin", Anal. Biochem., Vol. 236(2)(1996), p.215-220, Refer to ABSTRACT, RESULTS, DISCUSSION	5-9
A	SPYCHER, M.O., "The calcium-dependent neutral protease of human blood platelets : a comparison of its effects on the receptors for von willebrand factor and for the Fc-fragment derived from IgG.", Adv. Exp. Med. Biol., Vol. 167 (1984), p.241-251, Refer to ABSTRACT, RESULTS, DISCUSSION	1-2, 6-8, 12-13
A	SPYCHER, M.O., "The calcium-dependent neutral protease of human blood platelets : a comparison of its effects on the receptors for von willebrand factor and for the Fc-fragment derived from IgG.", Adv. Exp. Med. Biol., Vol. 167 (1984), p.241-251, Refer to ABSTRACT, RESULTS, DISCUSSION	3, 9, 14

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 11 March, 1999 (11. 03. 99)	Date of mailing of the international search report 23 March, 1999 (23. 03. 99)
Name and mailing address of the ISA/ Japanese Patent Office	Authorized officer
Facsimile No.	Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT		International application No. PCT/JP99/00089
C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP, 8-333400, A (Ajinomoto Co., Inc.), 17 December, 1996 (17. 12. 96), Refer to Claims ; Par. Nos. [0003] to [0006], [0016] ; Examples (Family: none)	5-20
Form PCT/ISA/210 (continuation of second sheet) (July 1992)		

THIS PAGE BLANK (USPTO)